



UltraPly Bonding Adhesive Ardex (Ardex NZ)

Chemwatch Hazard Alert Code: 3

Chemwatch: 5516-58

Version No: 2.1

Safety Data Sheet according to the Health and Safety at Work (Hazardous Substances) Regulations 2017

Issue Date: 17/12/2021

Print Date: 20/12/2021

L.GHS.NZL.EN

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product Identifier

Product name	UltraPly Bonding Adhesive
Chemical Name	Not Applicable
Synonyms	Not Available
Proper shipping name	ADHESIVES containing flammable liquid
Chemical formula	Not Applicable
Other means of identification	Not Available

Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses	Adhesive.
--------------------------	-----------

Details of the supplier of the safety data sheet

Registered company name	Ardex (Ardex NZ)
Address	32 Lane Street Woolston Christchurch New Zealand
Telephone	+64 3384 3029
Fax	+64 3384 9779
Website	www.ardex.co.nz
Email	info@ardexnz.com

Emergency telephone number

Association / Organisation	NZ National Poisons Centre
Emergency telephone numbers	+64 3373 6900
Other emergency telephone numbers	0800 764 766 (NZ NPC)

SECTION 2 Hazards identification

Classification of the substance or mixture

Considered a Hazardous Substance according to the criteria of the New Zealand Hazardous Substances New Organisms legislation. Classified as Dangerous Goods for transport purposes.

Classification [1]	Flammable Liquids Category 2, Acute Toxicity (Oral) Category 4, Aspiration Hazard Category 1, Skin Corrosion/Irritation Category 2, Sensitisation (Skin) Category 1, Serious Eye Damage/Eye Irritation Category 2, Specific Target Organ Toxicity - Single Exposure (Narcotic Effects) Category 3, Carcinogenicity Category 2, Reproductive Toxicity Category 2, Specific Target Organ Toxicity - Repeated Exposure Category 2, Hazardous to the Aquatic Environment Long-Term Hazard Category 3
Legend:	1. Classified by Chemwatch; 2. Classification drawn from CCID EPA NZ; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI
Determined by Chemwatch using GHS/HSNO criteria	3.1B, 6.1D (oral), 6.1E (aspiration), 6.3A, 6.4A, 6.5B (contact), 6.7B, 6.8B, 6.9B, 9.1C

Label elements

Hazard pictogram(s)	  
---------------------	---

UltraPly Bonding Adhesive

Signal word	Danger
-------------	--------

Hazard statement(s)

H225	Highly flammable liquid and vapour.
H302	Harmful if swallowed.
H304	May be fatal if swallowed and enters airways.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H336	May cause drowsiness or dizziness.
H351	Suspected of causing cancer.
H361	Suspected of damaging fertility or the unborn child.
H373	May cause damage to organs through prolonged or repeated exposure.
H412	Harmful to aquatic life with long lasting effects.

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.
P210	Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P260	Do not breathe mist/vapours/spray.
P271	Use only outdoors or in a well-ventilated area.
P280	Wear protective gloves, protective clothing, eye protection and face protection.
P240	Ground and bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/intrinsically safe equipment.
P242	Use non-sparking tools.
P243	Take action to prevent static discharges.
P264	Wash all exposed external body areas thoroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P273	Avoid release to the environment.
P272	Contaminated work clothing should not be allowed out of the workplace.

Precautionary statement(s) Response

P301+P310	IF SWALLOWED: Immediately call a POISON CENTER/doctor/physician/first aider.
P331	Do NOT induce vomiting.
P308+P313	IF exposed or concerned: Get medical advice/ attention.
P370+P378	In case of fire: Use alcohol resistant foam or normal protein foam to extinguish.
P302+P352	IF ON SKIN: Wash with plenty of water and soap.
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.
P337+P313	If eye irritation persists: Get medical advice/attention.
P362+P364	Take off contaminated clothing and wash it before reuse.
P301+P312	IF SWALLOWED: Call a POISON CENTER/doctor/physician/first aider if you feel unwell.
P303+P361+P353	IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water [or shower].
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P330	Rinse mouth.

Precautionary statement(s) Storage

P403+P235	Store in a well-ventilated place. Keep cool.
P405	Store locked up.

Precautionary statement(s) Disposal

P501	Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.
------	--

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
108-88-3	34-44	toluene
64741-84-0	25-35	naphtha petroleum, light solvent-refined

Continued...

CAS No	%[weight]	Name
9010-98-4	<12	chloroprene homopolymer
67-64-1	5-10	acetone
1330-20-7	<1	xylene
100-42-5	<1	styrene
1309-48-4	<1	magnesium oxide
1314-13-2	<0.3	zinc oxide
Legend: 1. Classified by Chemwatch; 2. Classification drawn from CCID EPA NZ; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L; * EU IOELVs available		

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	<p>If this product comes in contact with the eyes:</p> <ul style="list-style-type: none"> ▶ Wash out immediately with fresh running water. ▶ Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. ▶ Seek medical attention without delay; if pain persists or recurs seek medical attention. ▶ Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.
Skin Contact	<p>If skin or hair contact occurs:</p> <ul style="list-style-type: none"> ▶ Immediately flush body and clothes with large amounts of water, using safety shower if available. ▶ Quickly remove all contaminated clothing, including footwear. ▶ Wash skin and hair with running water. Continue flushing with water until advised to stop by the Poisons Information Centre. ▶ Transport to hospital, or doctor.
Inhalation	<ul style="list-style-type: none"> ▶ If fumes or combustion products are inhaled remove from contaminated area. ▶ Lay patient down. Keep warm and rested. ▶ Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures. ▶ Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary. ▶ Transport to hospital, or doctor, without delay.
Ingestion	<ul style="list-style-type: none"> ▶ Avoid giving milk or oils. ▶ Avoid giving alcohol. ▶ For advice, contact a Poisons Information Centre or a doctor at once. ▶ Urgent hospital treatment is likely to be needed. ▶ If swallowed do NOT induce vomiting. ▶ If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration. ▶ Observe the patient carefully. ▶ Never give liquid to a person showing signs of being sleepy or with reduced awareness; i.e. becoming unconscious. ▶ Give water to rinse out mouth, then provide liquid slowly and as much as casualty can comfortably drink. ▶ Transport to hospital or doctor without delay.

Indication of any immediate medical attention and special treatment needed

Any material aspirated during vomiting may produce lung injury. Therefore emesis should not be induced mechanically or pharmacologically. Mechanical means should be used if it is considered necessary to evacuate the stomach contents; these include gastric lavage after endotracheal intubation. If spontaneous vomiting has occurred after ingestion, the patient should be monitored for difficult breathing, as adverse effects of aspiration into the lungs may be delayed up to 48 hours. Treat symptomatically.

SECTION 5 Firefighting measures

Extinguishing media

- ▶ Foam.
- ▶ Dry chemical powder.
- ▶ BCF (where regulations permit).
- ▶ Carbon dioxide.
- ▶ Water spray or fog - Large fires only.

Special hazards arising from the substrate or mixture

Fire Incompatibility	▶ Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result
-----------------------------	--

Advice for firefighters

Fire Fighting	<ul style="list-style-type: none"> ▶ Alert Fire Brigade and tell them location and nature of hazard. ▶ May be violently or explosively reactive. ▶ Wear breathing apparatus plus protective gloves in the event of a fire. ▶ Prevent, by any means available, spillage from entering drains or water course. ▶ Consider evacuation (or protect in place). ▶ Fight fire from a safe distance, with adequate cover. ▶ If safe, switch off electrical equipment until vapour fire hazard removed. ▶ Use water delivered as a fine spray to control the fire and cool adjacent area. ▶ Avoid spraying water onto liquid pools. ▶ Do not approach containers suspected to be hot. ▶ Cool fire exposed containers with water spray from a protected location. ▶ If safe to do so, remove containers from path of fire.
Fire/Explosion Hazard	<ul style="list-style-type: none"> ▶ Liquid and vapour are highly flammable. ▶ Severe fire hazard when exposed to heat, flame and/or oxidisers. ▶ Vapour may travel a considerable distance to source of ignition. ▶ Heating may cause expansion or decomposition leading to violent rupture of containers.

▶ On combustion, may emit toxic fumes of carbon monoxide (CO).
 Combustion products include:
 carbon dioxide (CO₂)
 hydrogen chloride
 phosgene
 metal oxides
 other pyrolysis products typical of burning organic material.
Contains low boiling substance: Closed containers may rupture due to pressure buildup under fire conditions.
 May emit clouds of acrid smoke

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	<ul style="list-style-type: none"> ▶ Remove all ignition sources. ▶ Clean up all spills immediately. ▶ Avoid breathing vapours and contact with skin and eyes. ▶ Control personal contact with the substance, by using protective equipment. ▶ Contain and absorb small quantities with vermiculite or other absorbent material. ▶ Wipe up. ▶ Collect residues in a flammable waste container.
Major Spills	<ul style="list-style-type: none"> ▶ Clear area of personnel and move upwind. ▶ Alert Fire Brigade and tell them location and nature of hazard. ▶ May be violently or explosively reactive. ▶ Wear breathing apparatus plus protective gloves. ▶ Prevent, by any means available, spillage from entering drains or water course. ▶ Consider evacuation (or protect in place). ▶ No smoking, naked lights or ignition sources. ▶ Increase ventilation. ▶ Stop leak if safe to do so. ▶ Water spray or fog may be used to disperse /absorb vapour. ▶ Contain spill with sand, earth or vermiculite. ▶ Use only spark-free shovels and explosion proof equipment. ▶ Collect recoverable product into labelled containers for recycling. ▶ Absorb remaining product with sand, earth or vermiculite. ▶ Collect solid residues and seal in labelled drums for disposal. ▶ Wash area and prevent runoff into drains. ▶ If contamination of drains or waterways occurs, advise emergency services.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling

Safe handling	<p>The conductivity of this material may make it a static accumulator., A liquid is typically considered nonconductive if its conductivity is below 100 pS/m and is considered semi-conductive if its conductivity is below 10 000 pS/m., Whether a liquid is nonconductive or semi-conductive, the precautions are the same., A number of factors, for example liquid temperature, presence of contaminants, and anti-static additives can greatly influence the conductivity of a liquid.</p> <ul style="list-style-type: none"> ▶ Containers, even those that have been emptied, may contain explosive vapours. ▶ Do NOT cut, drill, grind, weld or perform similar operations on or near containers. <p>Contains low boiling substance: Storage in sealed containers may result in pressure buildup causing violent rupture of containers not rated appropriately.</p> <ul style="list-style-type: none"> ▶ Check for bulging containers. ▶ Vent periodically ▶ Always release caps or seals slowly to ensure slow dissipation of vapours ▶ DO NOT allow clothing wet with material to stay in contact with skin ▶ Electrostatic discharge may be generated during pumping - this may result in fire. ▶ Ensure electrical continuity by bonding and grounding (earthing) all equipment. ▶ Restrict line velocity during pumping in order to avoid generation of electrostatic discharge (<=1 m/sec until fill pipe submerged to twice its diameter, then <= 7 m/sec). ▶ Avoid splash filling. ▶ Do NOT use compressed air for filling discharging or handling operations. ▶ Avoid all personal contact, including inhalation. ▶ Wear protective clothing when risk of exposure occurs. ▶ Use in a well-ventilated area. ▶ Prevent concentration in hollows and sumps. ▶ DO NOT enter confined spaces until atmosphere has been checked. ▶ Avoid smoking, naked lights, heat or ignition sources. ▶ When handling, DO NOT eat, drink or smoke. ▶ Vapour may ignite on pumping or pouring due to static electricity. ▶ DO NOT use plastic buckets. ▶ Earth and secure metal containers when dispensing or pouring product. ▶ Use spark-free tools when handling. ▶ Avoid contact with incompatible materials. ▶ Keep containers securely sealed. ▶ Avoid physical damage to containers. ▶ Always wash hands with soap and water after handling. ▶ Work clothes should be laundered separately.
----------------------	---

	<ul style="list-style-type: none"> ▶ Use good occupational work practice. ▶ Observe manufacturer's storage and handling recommendations contained within this SDS. ▶ Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions.
Other information	<ul style="list-style-type: none"> ▶ Store in original containers in approved flame-proof area. ▶ No smoking, naked lights, heat or ignition sources. ▶ DO NOT store in pits, depressions, basements or areas where vapours may be trapped. ▶ Keep containers securely sealed. ▶ Store away from incompatible materials in a cool, dry well ventilated area. ▶ Protect containers against physical damage and check regularly for leaks. ▶ Observe manufacturer's storage and handling recommendations contained within this SDS.

Conditions for safe storage, including any incompatibilities

Suitable container	<ul style="list-style-type: none"> ▶ Packing as supplied by manufacturer. ▶ Plastic containers may only be used if approved for flammable liquid. ▶ Check that containers are clearly labelled and free from leaks. ▶ For low viscosity materials (i) : Drums and jerry cans must be of the non-removable head type. (ii) : Where a can is to be used as an inner package, the can must have a screwed enclosure. ▶ For materials with a viscosity of at least 2680 cSt. (23 deg. C) ▶ For manufactured product having a viscosity of at least 250 cSt. (23 deg. C) ▶ Manufactured product that requires stirring before use and having a viscosity of at least 20 cSt (25 deg. C): (i) Removable head packaging; (ii) Cans with friction closures and (iii) low pressure tubes and cartridges may be used. ▶ Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact with inner and outer packages ▶ In addition, where inner packagings are glass and contain liquids of packing group I there must be sufficient inert absorbent to absorb any spillage, unless the outer packaging is a close fitting moulded plastic box and the substances are not incompatible with the plastic.
Storage incompatibility	<ul style="list-style-type: none"> ▶ Avoid reaction with oxidising agents ▶ Avoid strong acids, bases.

SECTION 8 Exposure controls / personal protection**Control parameters****Occupational Exposure Limits (OEL)****INGREDIENT DATA**

Source	Ingredient	Material name	TWA	STEL	Peak	Notes
New Zealand Workplace Exposure Standards (WES)	toluene	Toluene (Toluol)	50 ppm / 188 mg/m3	Not Available	Not Available	skin-Skin absorption
New Zealand Workplace Exposure Standards (WES)	naphtha petroleum, light solvent-refined	Oil mist, mineral	5 mg/m3	10 mg/m3	Not Available	om-Sampled by a method that does not collect vapour.
New Zealand Workplace Exposure Standards (WES)	chloroprene homopolymer	Particulates not otherwise classified respirable dust	3 mg/m3	Not Available	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	chloroprene homopolymer	Diesel Particulate Matter (DPM) as elemental carbon	0.1 mg/m3	Not Available	Not Available	diesel engine exhaust is a confirmed carcinogen
New Zealand Workplace Exposure Standards (WES)	chloroprene homopolymer	Particulates not otherwise classified	10 mg/m3	Not Available	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	acetone	Acetone	500 ppm / 1185 mg/m3	2375 mg/m3 / 1000 ppm	Not Available	bio-Exposure can also be estimated by biological monitoring.
New Zealand Workplace Exposure Standards (WES)	xylene	Dimethylbenzene	50 ppm / 217 mg/m3	Not Available	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	styrene	Styrene monomer (Phenylethylene, vinyl benzene)	20 ppm / 85 mg/m3	170 mg/m3 / 40 ppm	Not Available	6.7B-Suspected carcinogen
New Zealand Workplace Exposure Standards (WES)	magnesium oxide	Magnesium oxide fume	10 mg/m3	Not Available	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	zinc oxide	Zinc oxide fume respirable dust	3 mg/m3	10 mg/m3	Not Available	Not Available
New Zealand Workplace Exposure Standards (WES)	zinc oxide	Zinc oxide Dust respirable dust	10 mg/m3	Not Available	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
toluene	Not Available	Not Available	Not Available
naphtha petroleum, light solvent-refined	140 mg/m3	1,500 mg/m3	8,900 mg/m3
acetone	Not Available	Not Available	Not Available
xylene	Not Available	Not Available	Not Available
styrene	Not Available	Not Available	Not Available
magnesium oxide	30 mg/m3	120 mg/m3	730 mg/m3
zinc oxide	10 mg/m3	15 mg/m3	2,500 mg/m3

Ingredient	Original IDLH	Revised IDLH
toluene	500 ppm	Not Available

UltraPly Bonding Adhesive

Ingredient	Original IDLH	Revised IDLH
naphtha petroleum, light solvent-refined	2,500 mg/m3	Not Available
chloroprene homopolymer	Not Available	Not Available
acetone	2,500 ppm	Not Available
xylene	900 ppm	Not Available
styrene	700 ppm	Not Available
magnesium oxide	750 mg/m3	Not Available
zinc oxide	500 mg/m3	Not Available

MATERIAL DATA

NOTE D: Certain substances which are susceptible to spontaneous polymerisation or decomposition are generally placed on the market in a stabilised form. It is in this form that they are listed on Annex I

When they are placed on the market in a non-stabilised form, the label must state the name of the substance followed by the words "non-stabilised"

European Union (EU) List of harmonised classification and labelling hazardous substances, Table 3.1, Annex VI, Regulation (EC) No 1272/2008 (CLP) - up to the latest ATP

NOTE P: The classification as a carcinogen need not apply if it can be shown that the substance contains less than 0.01% w/w benzene (EINECS No 200-753-7). Note E shall also apply when the substance is classified as a carcinogen. This note applies only to certain complex oil-derived substances in Annex VI.

European Union (EU) List of harmonised classification and labelling hazardous substances, Table 3.1, Annex VI, Regulation (EC) No 1272/2008 (CLP) - up to the latest ATP

Exposure controls

<p>Appropriate engineering controls</p>	<p>Engineering controls are used to remove a hazard or place a barrier between the worker and the hazard. Well-designed engineering controls can be highly effective in protecting workers and will typically be independent of worker interactions to provide this high level of protection.</p> <p>The basic types of engineering controls are:</p> <p>Process controls which involve changing the way a job activity or process is done to reduce the risk.</p> <p>Enclosure and/or isolation of emission source which keeps a selected hazard "physically" away from the worker and ventilation that strategically "adds" and "removes" air in the work environment. Ventilation can remove or dilute an air contaminant if designed properly. The design of a ventilation system must match the particular process and chemical or contaminant in use.</p> <p>Employers may need to use multiple types of controls to prevent employee overexposure.</p> <ul style="list-style-type: none"> ▶ Employees exposed to confirmed human carcinogens should be authorized to do so by the employer, and work in a regulated area. ▶ Work should be undertaken in an isolated system such as a "glove-box" . Employees should wash their hands and arms upon completion of the assigned task and before engaging in other activities not associated with the isolated system. ▶ Within regulated areas, the carcinogen should be stored in sealed containers, or enclosed in a closed system, including piping systems, with any sample ports or openings closed while the carcinogens are contained within. ▶ Open-vessel systems are prohibited. ▶ Each operation should be provided with continuous local exhaust ventilation so that air movement is always from ordinary work areas to the operation. ▶ Exhaust air should not be discharged to regulated areas, non-regulated areas or the external environment unless decontaminated. Clean make-up air should be introduced in sufficient volume to maintain correct operation of the local exhaust system. ▶ For maintenance and decontamination activities, authorized employees entering the area should be provided with and required to wear clean, impervious garments, including gloves, boots and continuous-air supplied hood. Prior to removing protective garments the employee should undergo decontamination and be required to shower upon removal of the garments and hood. ▶ Except for outdoor systems, regulated areas should be maintained under negative pressure (with respect to non-regulated areas). ▶ Local exhaust ventilation requires make-up air be supplied in equal volumes to replaced air. ▶ Laboratory hoods must be designed and maintained so as to draw air inward at an average linear face velocity of 0.76 m/sec with a minimum of 0.64 m/sec. Design and construction of the fume hood requires that insertion of any portion of the employees body, other than hands and arms, be disallowed. <p>CARE: Use of a quantity of this material in confined space or poorly ventilated area, where rapid build up of concentrated atmosphere may occur, could require increased ventilation and/or protective gear</p>
<p>Personal protection</p>	
<p>Eye and face protection</p>	<ul style="list-style-type: none"> ▶ Safety glasses with side shields. ▶ Chemical goggles. ▶ Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]
<p>Skin protection</p>	<p>See Hand protection below</p>
<p>Hands/feet protection</p>	<ul style="list-style-type: none"> ▶ Wear chemical protective gloves, e.g. PVC. ▶ Wear safety footwear or safety gumboots, e.g. Rubber <p>NOTE:</p> <ul style="list-style-type: none"> ▶ The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact. ▶ Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed. <p>The selection of suitable gloves does not only depend on the material, but also on further marks of quality which vary from manufacturer to manufacturer. Where the chemical is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.</p> <p>The exact break through time for substances has to be obtained from the manufacturer of the protective gloves and has to be observed when making a final choice.</p> <p>Personal hygiene is a key element of effective hand care. Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.</p> <p>Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:</p> <ul style="list-style-type: none"> · frequency and duration of contact, · chemical resistance of glove material, · glove thickness and

	<ul style="list-style-type: none"> dexterity <p>Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).</p> <ul style="list-style-type: none"> When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended. Some glove polymer types are less affected by movement and this should be taken into account when considering gloves for long-term use. Contaminated gloves should be replaced. <p>As defined in ASTM F-739-96 in any application, gloves are rated as:</p> <ul style="list-style-type: none"> Excellent when breakthrough time > 480 min Good when breakthrough time > 20 min Fair when breakthrough time < 20 min Poor when glove material degrades <p>For general applications, gloves with a thickness typically greater than 0.35 mm, are recommended.</p> <p>It should be emphasised that glove thickness is not necessarily a good predictor of glove resistance to a specific chemical, as the permeation efficiency of the glove will be dependent on the exact composition of the glove material. Therefore, glove selection should also be based on consideration of the task requirements and knowledge of breakthrough times.</p> <p>Glove thickness may also vary depending on the glove manufacturer, the glove type and the glove model. Therefore, the manufacturers' technical data should always be taken into account to ensure selection of the most appropriate glove for the task.</p> <p>Note: Depending on the activity being conducted, gloves of varying thickness may be required for specific tasks. For example:</p> <ul style="list-style-type: none"> Thinner gloves (down to 0.1 mm or less) may be required where a high degree of manual dexterity is needed. However, these gloves are only likely to give short duration protection and would normally be just for single use applications, then disposed of. Thicker gloves (up to 3 mm or more) may be required where there is a mechanical (as well as a chemical) risk i.e. where there is abrasion or puncture potential <p>Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.</p>
Body protection	See Other protection below
Other protection	<ul style="list-style-type: none"> Employees working with confirmed human carcinogens should be provided with, and be required to wear, clean, full body protective clothing (smocks, coveralls, or long-sleeved shirt and pants), shoe covers and gloves prior to entering the regulated area. [AS/NZS ISO 6529:2006 or national equivalent] Employees engaged in handling operations involving carcinogens should be provided with, and required to wear and use half-face filter-type respirators with filters for dusts, mists and fumes, or air purifying canisters or cartridges. A respirator affording higher levels of protection may be substituted. [AS/NZS 1715 or national equivalent] Emergency deluge showers and eyewash fountains, supplied with potable water, should be located near, within sight of, and on the same level with locations where direct exposure is likely. Prior to each exit from an area containing confirmed human carcinogens, employees should be required to remove and leave protective clothing and equipment at the point of exit and at the last exit of the day, to place used clothing and equipment in impervious containers at the point of exit for purposes of decontamination or disposal. The contents of such impervious containers must be identified with suitable labels. For maintenance and decontamination activities, authorized employees entering the area should be provided with and required to wear clean, impervious garments, including gloves, boots and continuous-air supplied hood. Prior to removing protective garments the employee should undergo decontamination and be required to shower upon removal of the garments and hood. Overalls. PVC Apron. PVC protective suit may be required if exposure severe. Eyewash unit. Ensure there is ready access to a safety shower. Some plastic personal protective equipment (PPE) (e.g. gloves, aprons, overshoes) are not recommended as they may produce static electricity. For large scale or continuous use wear tight-weave non-static clothing (no metallic fasteners, cuffs or pockets). Non sparking safety or conductive footwear should be considered. Conductive footwear describes a boot or shoe with a sole made from a conductive compound chemically bound to the bottom components, for permanent control to electrically ground the foot an shall dissipate static electricity from the body to reduce the possibility of ignition of volatile compounds. Electrical resistance must range between 0 to 500,000 ohms. Conductive shoes should be stored in lockers close to the room in which they are worn. Personnel who have been issued conductive footwear should not wear them from their place of work to their homes and return.

Recommended material(s)

GLOVE SELECTION INDEX

Glove selection is based on a modified presentation of the:

"Forsberg Clothing Performance Index".

The effect(s) of the following substance(s) are taken into account in the **computer-generated** selection:

UltraPly Bonding Adhesive

Material	CPI
PE/EVAL/PE	A
TEFLON	B
BUTYL	C
BUTYL/NEOPRENE	C
CPE	C
HYPALON	C
NAT+NEOPR+NITRILE	C
NATURAL RUBBER	C
NATURAL+NEOPRENE	C
NEOPRENE	C
NEOPRENE/NATURAL	C
NITRILE	C
NITRILE+PVC	C

Respiratory protection

Type AX Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Where the concentration of gas/particulates in the breathing zone, approaches or exceeds the "Exposure Standard" (or ES), respiratory protection is required.

Degree of protection varies with both face-piece and Class of filter; the nature of protection varies with Type of filter.

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	AX-AUS	-	AX-PAPR-AUS / Class 1
up to 50 x ES	-	AX-AUS / Class 1	-
up to 100 x ES	-	AX-2	AX-PAPR-2 ^

^ - Full-face

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO₂), G = Agricultural chemicals, K = Ammonia(NH₃), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- Cartridge respirators should never be used for emergency ingress or in areas of unknown vapour concentrations or oxygen content.
- The wearer must be warned to leave the contaminated area immediately on detecting any odours through the respirator. The odour may indicate that the mask is not functioning properly, that the vapour concentration is too high, or that the mask is

Continued...

UltraPly Bonding Adhesive

PVA	C
PVC	C
PVDC/PE/PVDC	C
SARANEX-23	C
SARANEX-23 2-PLY	C
VITON	C
VITON/CHLOROBUTYL	C
VITON/NEOPRENE	C

* CPI - Chemwatch Performance Index

A: Best Selection

B: Satisfactory; may degrade after 4 hours continuous immersion

C: Poor to Dangerous Choice for other than short term immersion

NOTE: As a series of factors will influence the actual performance of the glove, a final selection must be based on detailed observation. -

* Where the glove is to be used on a short term, casual or infrequent basis, factors such as "feel" or convenience (e.g. disposability), may dictate a choice of gloves which might otherwise be unsuitable following long-term or frequent use. A qualified practitioner should be consulted.

not properly fitted. Because of these limitations, only restricted use of cartridge respirators is considered appropriate.

- ▶ Cartridge performance is affected by humidity. Cartridges should be changed after 2 hr of continuous use unless it is determined that the humidity is less than 75%, in which case, cartridges can be used for 4 hr. Used cartridges should be discarded daily, regardless of the length of time used

Selection of the Class and Type of respirator will depend upon the level of breathing zone contaminant and the chemical nature of the contaminant. Protection Factors (defined as the ratio of contaminant outside and inside the mask) may also be important.

Required minimum protection factor	Maximum gas/vapour concentration present in air p.p.m. (by volume)	Half-face Respirator	Full-Face Respirator
up to 10	1000	AX-AUS / Class 1	-
up to 50	1000	-	AX-AUS / Class 1
up to 50	5000	Airline *	-
up to 100	5000	-	AX-2
up to 100	10000	-	AX-3
100+		-	Airline**

** - Continuous-flow or positive pressure demand.

A(All classes) = Organic vapours, B AUS or B1 = Acid gases, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO₂), G = Agricultural chemicals, K = Ammonia(NH₃), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 deg C)

SECTION 9 Physical and chemical properties

Information on basic physical and chemical properties

Appearance	Yellow amber highly flammable liquid with strong aromatic odour; does not mix with water.		
Physical state	Liquid	Relative density (Water = 1)	0.844
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Applicable	Decomposition temperature	Not Available
Melting point / freezing point (°C)	Not Applicable	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	<61	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	-18	Taste	Not Available
Evaporation rate	1.5-9.5 BuAC = 1	Explosive properties	Not Available
Flammability	HIGHLY FLAMMABLE.	Oxidising properties	Not Available
Upper Explosive Limit (%)	7.5	Surface Tension (dyn/cm or mN/m)	Not Available
Lower Explosive Limit (%)	1.1	Volatile Component (%vol)	76.4
Vapour pressure (kPa)	1.3-25 @20C	Gas group	Not Available
Solubility in water	Immiscible	pH as a solution (%)	Not Applicable
Vapour density (Air = 1)	>3	VOC g/L	633

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	<ul style="list-style-type: none"> ▶ Unstable in the presence of incompatible materials. ▶ Product is considered stable. ▶ Hazardous polymerisation will not occur.
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo. Inhalation hazard is increased at higher temperatures.
----------------	--

Acute effects from inhalation of high concentrations of vapour are pulmonary irritation, including coughing, with nausea; central nervous system depression - characterised by headache and dizziness, increased reaction time, fatigue and loss of co-ordination. Central nervous system (CNS) depression may include nonspecific discomfort, symptoms of giddiness, headache, dizziness, nausea, anaesthetic effects, slowed reaction time, slurred speech and may progress to unconsciousness. Serious poisonings may result in respiratory depression and may be fatal.

High inhaled concentrations of mixed hydrocarbons may produce narcosis characterised by nausea, vomiting and lightheadedness. Inhalation of aerosols may produce severe pulmonary oedema, pneumonitis and pulmonary haemorrhage. Inhalation of petroleum hydrocarbons consisting substantially of low molecular weight species (typically C2-C12) may produce irritation of mucous membranes, incoordination, giddiness, nausea, vertigo, confusion, headache, appetite loss, drowsiness, tremors and anaesthetic stupor. Massive exposures may produce central nervous system depression with sudden collapse and deep coma; fatalities have been recorded. Irritation of the brain and/or apnoeic anoxia may produce convulsions. Although recovery following overexposure is generally complete, cerebral micro-haemorrhage of focal post-inflammatory scarring may produce epileptiform seizures some months after the exposure. Pulmonary episodes may include chemical pneumonitis with oedema and haemorrhage. The lighter hydrocarbons may produce kidney and neurotoxic effects. Pulmonary irritancy increases with carbon chain length for paraffins and olefins. Alkenes produce pulmonary oedema at high concentrations. Liquid paraffins may produce anaesthesia and depressant actions leading to weakness, dizziness, slow and shallow respiration, unconsciousness, convulsions and death. C5-7 paraffins may also produce polyneuropathy. Aromatic hydrocarbons accumulate in lipid rich tissues (typically the brain, spinal cord and peripheral nerves) and may produce functional impairment manifested by nonspecific symptoms such as nausea, weakness, fatigue and vertigo; severe exposures may produce inebriation or unconsciousness. Many of the petroleum hydrocarbons are cardiac sensitisers and may cause ventricular fibrillations.

A significant number of individuals exposed to mixed trimethylbenzenes complained of nervousness, tension, anxiety and asthmatic bronchitis. Peripheral blood showed a tendency to hypochromic anaemia and a deviation from normal in coagulability of the blood. Hydrocarbon concentrations ranged from 10 to 60 ppm. Contamination of the mixture with benzene may have been responsible for the blood dyscrasias. High concentrations of mesitylene vapour (5000 to 9000 ppm) caused central nervous system depression in mice. Similar exposures of pseudocumene also produced evidence of CNS involvement.

Some aliphatic hydrocarbons produce axonal neuropathies. Isoparaffinic hydrocarbons produce injury to the kidneys of male rats. When albino rats were exposed to isoparaffins at 21.4 mg/l for 4 hours, all animals experienced weakness, tremors, salivation, mild to moderate convulsions, chromodacryorrhoea and ataxia within the first 24 hours. Symptoms disappeared after 24 hours.

Several studies have evaluated sensory irritation in laboratory animals or odor or sensory response in humans. When evaluated by a standard procedure to assess upper airway irritation, isoparaffins did not produce sensory irritation in mice exposed to up to 400 ppm isoparaffin in air. Human volunteers were exposed for six hours to 100 ppm isoparaffin. The subjects were given a self-administered questionnaire to evaluate symptoms, which included dryness of the mucous membranes, loss of appetite, nausea, vomiting, diarrhea, fatigue, headache, dizziness, feeling of inebriation, visual disturbances, tremor, muscular weakness, impairment of coordination or paresthesia. No symptoms associated with solvent exposure were observed. With a human expert panel, odour from liquid imaging copier emissions became weakly discernible at approximately 50 ppm.

Numerous long-term exposures have been conducted in animals with only one major finding observed. Renal tubular damage has been found in kidneys of male rats upon repeated exposures to isoparaffins. It does not occur in mice or in female rats. This male rat nephropathy has been observed with a number of hydrocarbons, including wholly vaporized unleaded gasoline. The phenomenon has been attributed to reversible binding of hydrocarbon to alpha2-globulin. Since humans do not synthesize alpha2-globulin or a similar protein, the finding is not considered to be of biological significance to man. No clinically significant renal abnormalities have been found in refinery workers exposed to hydrocarbons. When evaluated for developmental toxicity in rats, isoparaffins were neither embryotoxic nor teratogenic. Isoparaffins were consistently negative on standard bacterial genotoxicity assays. They were also non-genotoxic in *in vivo* mammalian testing for somatic or germ cell mutations (mouse micronucleus test and rat dominant lethal assay, respectively).

Mullin et al: Jnl Applied Toxicology 10, pp 136-142, 2006

The acute toxicity of inhaled alkylbenzenes is best described by central nervous system depression. As a rule, these compounds may also act as general anaesthetics.

Systemic poisoning produced by general anaesthesia is characterised by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting and sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness and respiratory depression and arrest. Cardiac arrest may result from cardiovascular collapse. Bradycardia, and hypotension may also be produced.

Inhaled alkylbenzene vapours cause death in animals at air levels that are relatively similar (typically LC50s are in the range 5000 -8000 ppm for 4 to 8 hour exposures). It is likely that acute inhalation exposure to alkylbenzenes resembles that to general anaesthetics.

Alkylbenzenes are not generally toxic other than at high levels of exposure. This may be because their metabolites have a low order of toxicity and are easily excreted. There is little or no evidence to suggest that metabolic pathways can become saturated leading to spillover to alternate pathways. Nor is there evidence that toxic reactive intermediates, which may produce subsequent toxic or mutagenic effects, are formed

Headache, fatigue, lassitude, irritability and gastrointestinal disturbances (e.g., nausea, anorexia and flatulence) are the most common symptoms of xylene overexposure. Injury to the heart, liver, kidneys and nervous system has also been noted amongst workers. Transient memory loss, renal impairment, temporary confusion and some evidence of disturbance of liver function was reported in three workers overcome by gross exposure to xylene (10000 ppm). One worker died and autopsy revealed pulmonary congestion, oedema and focal alveolar haemorrhage. Volunteers inhaling xylene at 100 ppm for 5 to 6 hours showed changes in manual coordination reaction time and slight ataxia. Tolerance developed during the workweek but was lost over the weekend. Physical exercise may antagonise this effect. Xylene body burden in humans exposed to 100 or 200 ppm xylene in air depends on the amount of body fat with 4% to 8% of total absorbed xylene accumulating in adipose tissue.

Xylene is a central nervous system depressant. Central nervous system (CNS) depression may include nonspecific discomfort, symptoms of giddiness, headache, dizziness, nausea, anaesthetic effects, slowed reaction time, slurred speech and may progress to unconsciousness. Serious poisonings may result in respiratory depression and may be fatal.

Limited evidence or practical experience suggests that the material may produce irritation of the respiratory system, in a significant number of individuals, following inhalation. In contrast to most organs, the lung is able to respond to a chemical insult by first removing or neutralising the irritant and then repairing the damage. The repair process, which initially evolved to protect mammalian lungs from foreign matter and antigens, may however, produce further lung damage resulting in the impairment of gas exchange, the primary function of the lungs. Respiratory tract irritation often results in an inflammatory response involving the recruitment and activation of many cell types, mainly derived from the vascular system.

Ingestion

Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.

Swallowing of the liquid may cause aspiration of vomit into the lungs with the risk of haemorrhaging, pulmonary oedema, progressing to chemical pneumonitis; serious consequences may result.

Signs and symptoms of chemical (aspiration) pneumonitis may include coughing, gasping, choking, burning of the mouth, difficult breathing, and bluish coloured skin (cyanosis).

Many aliphatic hydrocarbons create a burning sensation because they are irritating to the GI mucosa. Vomiting has been reported in up to one third of all hydrocarbon exposures. While most aliphatic hydrocarbons have little GI absorption, aspiration frequently occurs, either initially or in a semi-delayed fashion as the patient coughs or vomits, thereby resulting in pulmonary effects. Once aspirated, the hydrocarbons can create a severe pneumonitis.

Rats given isoparaffinic hydrocarbons - isoalkanes- (after 18-24 hours fasting) showed lethargy and/or general weakness, ataxia and diarrhoea. Symptoms disappeared within 24-28 hours.

At sufficiently high doses the material may be hepatotoxic (i.e. poisonous to the liver). Signs may include nausea, stomach pains, low fever, loss of appetite, dark urine, clay-coloured stools, jaundice (yellowing of the skin or eyes)

Ingestion of petroleum hydrocarbons may produce irritation of the pharynx, oesophagus, stomach and small intestine with oedema and mucosal ulceration resulting; symptoms include a burning sensation in the mouth and throat. Large amounts may produce narcosis with nausea and

	<p>vomiting, weakness or dizziness, slow and shallow respiration, swelling of the abdomen, unconsciousness and convulsions. Myocardial injury may produce arrhythmias, ventricular fibrillation and electrocardiographic changes. Central nervous system depression may also occur. Light aromatic hydrocarbons produce a warm, sharp, tingling sensation on contact with taste buds and may anaesthetise the tongue. Aspiration into the lungs may produce coughing, gagging and a chemical pneumonitis with pulmonary oedema and haemorrhage. Considered an unlikely route of entry in commercial/industrial environments. The liquid may produce gastrointestinal discomfort and may be harmful if swallowed. Ingestion may result in nausea, pain and vomiting. Vomit entering the lungs by aspiration may cause potentially lethal chemical pneumonitis</p>
<p>Skin Contact</p>	<p>The material produces moderate skin irritation; evidence exists, or practical experience predicts, that the material either</p> <ul style="list-style-type: none"> ▶ produces moderate inflammation of the skin in a substantial number of individuals following direct contact, and/or ▶ produces significant, but moderate, inflammation when applied to the healthy intact skin of animals (for up to four hours), such inflammation being present twenty-four hours or more after the end of the exposure period. <p>Skin irritation may also be present after prolonged or repeated exposure; this may result in a form of contact dermatitis (nonallergic). The dermatitis is often characterised by skin redness (erythema) and swelling (oedema) which may progress to blistering (vesiculation), scaling and thickening of the epidermis. At the microscopic level there may be intercellular oedema of the spongy layer of the skin (spongiosis) and intracellular oedema of the epidermis.</p> <p>Repeated exposure may cause skin cracking, flaking or drying following normal handling and use.</p> <p>Skin contact with the material may damage the health of the individual; systemic effects may result following absorption.</p> <p>Dermally, isoparaffins have produced slight to moderate irritation in animals and humans under occluded patch conditions where evaporation cannot freely occur. However, they are not irritating in non-occluded tests, which are a more realistic simulation of human exposure. They have not been found to be sensitisers in guinea pig or human patch testing. However, occasional rare idiosyncratic sensitisation reactions in humans have been reported.</p> <p>Open cuts, abraded or irritated skin should not be exposed to this material</p> <p>Entry into the blood-stream through, for example, cuts, abrasions, puncture wounds or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.</p>
<p>Eye</p>	<p>Instillation of isoparaffins into rabbit eyes produces only slight irritation.</p> <p>Petroleum hydrocarbons may produce pain after direct contact with the eyes. Slight, but transient disturbances of the corneal epithelium may also result. The aromatic fraction may produce irritation and lachrymation.</p> <p>Evidence exists, or practical experience predicts, that the material may cause severe eye irritation in a substantial number of individuals and/or may produce significant ocular lesions which are present twenty-four hours or more after instillation into the eye(s) of experimental animals. Eye contact may cause significant inflammation with pain. Corneal injury may occur; permanent impairment of vision may result unless treatment is prompt and adequate. Repeated or prolonged exposure to irritants may cause inflammation characterised by a temporary redness (similar to windburn) of the conjunctiva (conjunctivitis); temporary impairment of vision and/or other transient eye damage/ulceration may occur.</p> <p>The liquid produces a high level of eye discomfort and is capable of causing pain and severe conjunctivitis. Corneal injury may develop, with possible permanent impairment of vision, if not promptly and adequately treated.</p>
<p>Chronic</p>	<p>Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.</p> <p>Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive.</p> <p>Substances that can cause occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers</p> <p>Wherever it is reasonably practicable, exposure to substances that can cause occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive.</p> <p>Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance.</p> <p>On the basis of epidemiological data, the material is regarded as carcinogenic to humans. There is sufficient data to establish a causal association between human exposure to the material and the development of cancer.</p> <p>There is sufficient evidence to provide a strong presumption that human exposure to the material may result in the development of heritable genetic damage, generally on the basis of</p> <ul style="list-style-type: none"> - appropriate animal studies, - other relevant information <p>Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed.</p> <p>Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests.</p> <p>There is sufficient evidence to establish a causal relationship between human exposure to the material and impaired fertility</p> <p>There is sufficient evidence to establish a causal relationship between human exposure to the material and subsequent developmental toxic effects in the off-spring.</p> <p>Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems.</p> <p>Implantation studies in rats show that paraffin oils may be tumourigen. As a general rule the highly refined paraffins contain a lower level of suspect polyaromatic hydrocarbons than less refined grades and also less than waxes derived from naphthenic base-stocks.</p> <p>Prolonged inhalation of high concentrations of magnesite (magnesium carbonate) dust caused pulmonary deposition and retention. Roasted magnesite (magnesium oxide) produced a greater degree of fibrosis than did crude magnesite. No cases of human systemic poisoning due to exposure to magnesite have been recorded. Pneumoconiosis was found in about 2% of workers exposed to high concentrations of dust from crude or roasted magnesite that also contained 1-3% silicon dioxide. Exposure periods ranged from 6-20 years. This condition occurred mainly in workers exposed to roasted (calcined) magnesite. The pneumoconiosis appeared to be "benign" and was often associated with chronic bronchitis and lung emphysema.</p> <p>In other reports the severity of the pneumoconiosis was associated with the crystalline silica content of the dust or in a case of magnesium carbonate used in insulating materials, the severity of the disease depended on the asbestos content.</p> <p>Complaints of coughing are rare amongst magnesite workers, and more frequent among dianase and grog (crushed refractory materials) workers.</p> <p>Airborne dust concentrations were lowest in dianase facilities but crystalline silica was high. Chronic bronchitis then, appears to increase where concentrations of crystalline silica are highest</p> <p>Repeated or prolonged exposure to mixed hydrocarbons may produce narcosis with dizziness, weakness, irritability, concentration and/or memory loss, tremor in the fingers and tongue, vertigo, olfactory disorders, constriction of visual field, paraesthesias of the extremities, weight loss and anaemia and degenerative changes in the liver and kidney. Chronic exposure by petroleum workers, to the lighter hydrocarbons, has been associated with visual disturbances, damage to the central nervous system, peripheral neuropathies (including numbness and paraesthesias), psychological and neurophysiological deficits, bone marrow toxicities (including hypoplasia possibly due to benzene) and hepatic and renal involvement. Chronic dermal exposure to petroleum hydrocarbons may result in defatting which produces localised dermatoses.</p> <p>Surface cracking and erosion may also increase susceptibility to infection by microorganisms. One epidemiological study of petroleum refinery workers has reported elevations in standard mortality ratios for skin cancer along with a dose-response relationship indicating an association</p>

between routine workplace exposure to petroleum or one of its constituents and skin cancer, particularly melanoma. Other studies have been unable to confirm this finding.

Hydrocarbon solvents are liquid hydrocarbon fractions derived from petroleum processing streams, containing only carbon and hydrogen atoms, with carbon numbers ranging from approximately C5-C20 and boiling between approximately 35-370 deg C. Many of the hydrocarbon solvents have complex and variable compositions with constituents of 4 types, alkanes (normal paraffins, isoparaffins, and cycloparaffins) and aromatics (primarily alkylated one- and two-ring species). Despite the compositional complexity, most hydrocarbon solvent constituents have similar toxicological properties, and the overall toxicological hazards can be characterized in generic terms. Hydrocarbon solvents can cause chemical pneumonitis if aspirated into the lung, and those that are volatile can cause acute CNS effects and/or ocular and respiratory irritation at exposure levels exceeding occupational recommendations. Otherwise, there are few toxicologically important effects. The exceptions, n-hexane and naphthalene, have unique toxicological properties

Animal studies:

No deaths or treatment related signs of toxicity were observed in rats exposed to light alkylate naphtha (paraffinic hydrocarbons) at concentrations of 668, 2220 and 6646 ppm for 6 hrs/day, 5 days/wk for 13 weeks. Increased liver weights and kidney toxicity (male rats) was observed in high dose animals. Exposure to pregnant rats at concentrations of 137, 3425 and 6850 ppm did not adversely affect reproduction or cause maternal or foetal toxicity. Lifetime skin painting studies in mice with similar naphthas have shown weak or no carcinogenic activity following prolonged and repeated exposure. Similar naphthas/distillates, when tested at nonirritating dose levels, did not show any significant carcinogenic activity indicating that this tumorigenic response is likely related to chronic irritation and not to dose. The mutagenic potential of naphthas has been reported to be largely negative in a variety of mutagenicity tests. The exact relationship between these results and human health is not known. Some components of this product have been shown to produce a species specific, sex hormonal dependent kidney lesion in male rats from repeated oral or inhalation exposure. Subsequent research has shown that the kidney damage develops via the formation of an alpha-2u-globulin, a mechanism unique to the male rat. Humans do not form alpha-2u-globulin, therefore, the kidney effects resulting from this mechanism are not relevant in human. Chronic toluene habituation occurs following intentional abuse (glue sniffing) or from occupational exposure. Ataxia, incoordination and tremors of the hands and feet (as a consequence of diffuse cerebral atrophy), headache, abnormal speech, transient memory loss, convulsions, coma, drowsiness, reduced colour perception, frank blindness, nystagmus (rapid, involuntary eye-movements), hearing loss leading to deafness and mild dementia have all been associated with chronic abuse. Peripheral nerve damage, encephalopathy, giant axonopathy electrolyte disturbances in the cerebrospinal fluid and abnormal computer tomographic (CT scans) are common amongst toluene addicts. Although toluene abuse has been linked with kidney disease, this does not commonly appear in cases of occupational toluene exposures. Cardiac and haematological toxicity are however associated with chronic toluene exposures. Cardiac arrhythmia, multifocal and premature ventricular contractions and supraventricular tachycardia are present in 20% of patients who abused toluene-containing paints. Previous suggestions that chronic toluene inhalation produced human peripheral neuropathy have been discounted. However central nervous system (CNS) depression is well documented where blood toluene exceeds 2.2 mg%. Toluene abusers can achieve transient circulating concentrations of 6.5 %. Amongst workers exposed for a median time of 29 years, to toluene, no subacute effects on neurasthenic complaints and psychometric test results could be established.

The prenatal toxicity of very high toluene concentrations has been documented for several animal species and man. Malformations indicative of specific teratogenicity have not generally been found. Neonatal toxicity, described in the literature, takes the form of embryo death or delayed foetal growth and delayed skeletal system development. Permanent damage of children has been seen only when mothers have suffered from chronic intoxication as a result of "sniffing".

Chronic low level exposures to hydrogen sulfide may produce headache, fatigue, dizziness, irritability and loss of libido. These symptoms may also result from damage produced by isolated or repeated unmeasured peak high level exposures in healthy persons or those suffering from pre-existing neurological diseases. A study on long term effects showed that H2S apparently can cause continuing, sometimes unrecognized olfactory deficits. [Hirsch, A.R. - *Occ. Env. Med.*, 1999, Vol 5, Iss 4, pp 284-287]

Prolonged or repeated contact with xylenes may cause defatting dermatitis with drying and cracking. Chronic inhalation of xylenes has been associated with central nervous system effects, loss of appetite, nausea, ringing in the ears, irritability, thirst anaemia, mucosal bleeding, enlarged liver and hyperplasia. Exposure may produce kidney and liver damage. In chronic occupational exposure, xylene (usually mixed with other solvents) has produced irreversible damage to the central nervous system and ototoxicity (damages hearing and increases sensitivity to noise), probably due to neurotoxic mechanisms.

Industrial workers exposed to xylene with a maximum level of ethyl benzene of 0.06 mg/l (14 ppm) reported headaches and irritability and tired quickly. Functional nervous system disturbances were found in some workers employed for over 7 years whilst other workers had enlarged livers.

Xylene has been classed as a developmental toxin in some jurisdictions.

Small excess risks of spontaneous abortion and congenital malformation were reported amongst women exposed to xylene in the first trimester of pregnancy. In all cases, however, the women were also been exposed to other substances. Evaluation of workers chronically exposed to xylene has demonstrated lack of genotoxicity. Exposure to xylene has been associated with increased risks of haemopoietic malignancies but, again, simultaneous exposure to other substances (including benzene) complicates the picture. A long-term gavage study to mixed xylenes (containing 17% ethyl benzene) found no evidence of carcinogenic activity in rats and mice of either sex.

Chronic exposure to benzene may cause headache, fatigue, loss of appetite and lassitude with incipient blood effects including anaemia and blood changes. Benzene is a myelotoxicant known to suppress bone-marrow cell proliferation and to induce haematologic disorders in humans and animals. Signs of benzene-induced aplastic anaemia include suppression of leukocytes (leukopenia), red cells (anaemia), platelets (thrombocytopenia) or all three cell types (pancytopenia). Classic symptoms include weakness, purpura, and haemorrhage. The most significant toxic effect is insidious and often reversible injury to the blood forming tissue. Leukaemia may develop. Occupational exposures have shown a relationship between exposure to benzene and production of myelogenous leukaemia. There may also be a relationship between benzene exposure and the production of lymphoma and multiple myeloma. In chronic exposure, workers exhibit signs of central nervous system lesions and impairment of hearing.

Benzene haemotoxicity and leukaemogenicity involve metabolism, growth factor regulation, oxidative stress, DNA damage, cell regulation, and apoptosis. (Yoon et al *Environmental Health Perspectives*, 111, pp 1411-1420, 2003)

UltraPly Bonding Adhesive	TOXICITY	IRRITATION
	Not Available	Not Available
toluene	TOXICITY	IRRITATION
	Dermal (rabbit) LD50: 12124 mg/kg ^[2]	Eye (rabbit): 2mg/24h - SEVERE
	Inhalation(Rat) LC50; >13350 ppm4h ^[2]	Eye (rabbit):0.87 mg - mild
	Oral (Rat) LD50; 636 mg/kg ^[2]	Eye (rabbit):100 mg/30sec - mild
		Eye: adverse effect observed (irritating) ^[1]
		Skin (rabbit):20 mg/24h-moderate
	Skin (rabbit):500 mg - moderate	
	Skin: adverse effect observed (irritating) ^[1]	

		Skin: no adverse effect observed (not irritating) ^[1]
naphtha petroleum, light solvent-refined	TOXICITY	IRRITATION
	Dermal (rabbit) LD50: >1900 mg/kg ^[1]	Eye: no adverse effect observed (not irritating) ^[1]
	Inhalation(Rat) LC50; >4.42 mg/L4h ^[1]	Skin: adverse effect observed (irritating) ^[1]
	Oral (Rat) LD50; 512 mg/kg ^[1]	
chloroprene homopolymer	TOXICITY	IRRITATION
	Oral (Rat) LD50; >40000 mg/kg ^[2]	Not Available
acetone	TOXICITY	IRRITATION
	Dermal (rabbit) LD50: 20000 mg/kg ^[2]	Eye (human): 500 ppm - irritant
	Inhalation(Mouse) LC50; 44 mg/L4h ^[2]	Eye (rabbit): 20mg/24hr - moderate
	Oral (Rat) LD50; 5800 mg/kg ^[2]	Eye (rabbit): 3.95 mg - SEVERE
		Eye: adverse effect observed (irritating) ^[1]
		Skin (rabbit): 500 mg/24hr - mild
		Skin (rabbit):395mg (open) - mild
	Skin: no adverse effect observed (not irritating) ^[1]	
xylene	TOXICITY	IRRITATION
	Dermal (rabbit) LD50: >1700 mg/kg ^[2]	Eye (human): 200 ppm irritant
	Inhalation(Rat) LC50; 5000 ppm4h ^[2]	Eye (rabbit): 5 mg/24h SEVERE
	Oral (Mouse) LD50; 2119 mg/kg ^[2]	Eye (rabbit): 87 mg mild
		Eye: adverse effect observed (irritating) ^[1]
		Skin (rabbit):500 mg/24h moderate
	Skin: adverse effect observed (irritating) ^[1]	
styrene	TOXICITY	IRRITATION
	dermal (rat) LD50: >2000 mg/kg ^[1]	Eye (rabbit): 100 mg/24h - moderate
	Inhalation(Mouse) LC50; 9.5 mg/L4h ^[2]	Eye (rabbit): 100 mg/24h - moderate
	Oral (Mouse) LD50; 316 mg/kg ^[2]	Skin (rabbit): 500 mg - mild
	Skin (rabbit): 500 mg - mild	
magnesium oxide	TOXICITY	IRRITATION
	Not Available	Not Available
zinc oxide	TOXICITY	IRRITATION
	dermal (rat) LD50: >2000 mg/kg ^[1]	Eye (rabbit) : 500 mg/24 h - mild
	Inhalation(Rat) LC50; >1.79 mg/4h ^[1]	Eye: no adverse effect observed (not irritating) ^[1]
	Oral (Rat) LD50; >5000 mg/kg ^[1]	Skin (rabbit) : 500 mg/24 h- mild
	Skin: no adverse effect observed (not irritating) ^[1]	

Legend: 1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2.* Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

TOLUENE	For toluene:
	Acute Toxicity
	Humans exposed to intermediate to high levels of toluene for short periods of time experience adverse central nervous system effects ranging from headaches to intoxication, convulsions, narcosis, and death. Similar effects are observed in short-term animal studies.
	Humans - Toluene ingestion or inhalation can result in severe central nervous system depression, and in large doses, can act as a narcotic. The ingestion of about 60 mL resulted in fatal nervous system depression within 30 minutes in one reported case.
	Constriction and necrosis of myocardial fibers, markedly swollen liver, congestion and haemorrhage of the lungs and acute tubular necrosis were found on autopsy.
	Central nervous system effects (headaches, dizziness, intoxication) and eye irritation occurred following inhalation exposure to 100 ppm toluene 6 hours/day for 4 days.
	Exposure to 600 ppm for 8 hours resulted in the same and more serious symptoms including euphoria, dilated pupils, convulsions, and nausea .
	Exposure to 10,000-30,000 ppm has been reported to cause narcosis and death
	Toluene can also strip the skin of lipids causing dermatitis
	Animals - The initial effects are instability and incoordination, lachrymation and sniffles (respiratory exposure), followed by narcosis. Animals die of respiratory failure from severe nervous system depression. Cloudy swelling of the kidneys was reported in rats following inhalation exposure to 1600 ppm, 18-20 hours/day for 3 days
Subchronic/Chronic Effects:	
Repeat doses of toluene cause adverse central nervous system effects and can damage the upper respiratory system, the liver, and the kidney. Adverse effects occur as a result from both oral and the inhalation exposures. A reported lowest-observed-effect level in humans for adverse neurobehavioral effects is 88 ppm.	
Humans - Chronic occupational exposure and incidences of toluene abuse have resulted in hepatomegaly and liver function changes. It has also resulted in nephrotoxicity and, in one case, was a cardiac sensitiser and fatal cardiotoxin.	

Neural and cerebellar dystrophy were reported in several cases of habitual "glue sniffing." An epidemiological study in France on workers chronically exposed to toluene fumes reported leukopenia and neutropenia. Exposure levels were not given in the secondary reference; however, the average urinary excretion of hippuric acid, a metabolite of toluene, was given as 4 g/L compared to a normal level of 0.6 g/L

Animals - The major target organs for the subchronic/chronic toxicity of toluene are the nervous system, liver, and kidney. Depressed immune response has been reported in male mice given doses of 105 mg/kg/day for 28 days. Toluene in corn oil administered to F344 male and female rats by gavage 5 days/week for 13 weeks, induced prostration, hypoactivity, ataxia, piloerection, lachrymation, excess salivation, and body tremors at doses 2500 mg/kg. Liver, kidney, and heart weights were also increased at this dose and histopathologic lesions were seen in the liver, kidneys, brain and urinary bladder. The no-observed-adverse effect level (NOAEL) for the study was 312 mg/kg (223 mg/kg/day) and the lowest-observed-adverse effect level (LOAEL) for the study was 625 mg/kg (446 mg/kg/day) .

Developmental/Reproductive Toxicity

Exposures to high levels of toluene can result in adverse effects in the developing human foetus. Several studies have indicated that high levels of toluene can also adversely effect the developing offspring in laboratory animals.

Humans - Variable growth, microcephaly, CNS dysfunction, attentional deficits, minor craniofacial and limb abnormalities, and developmental delay were seen in three children exposed to toluene in utero as a result of maternal solvent abuse before and during pregnancy

Animals - Sternebral alterations, extra ribs, and missing tails were reported following treatment of rats with 1500 mg/m³ toluene 24 hours/day during days 9-14 of gestation. Two of the dams died during the exposure. Another group of rats received 1000 mg/m³ 8 hours/day during days 1-21 of gestation. No maternal deaths or toxicity occurred, however, minor skeletal retardation was present in the exposed fetuses. CFLP Mice were exposed to 500 or 1500 mg/m³ toluene continuously during days 6-13 of pregnancy. All dams died at the high dose during the first 24 hours of exposure, however none died at 500 mg/m³. Decreased foetal weight was reported, but there were no differences in the incidences of skeletal malformations or anomalies between the treated and control offspring.

Absorption - Studies in humans and animals have demonstrated that toluene is readily absorbed via the lungs and the gastrointestinal tract.

Absorption through the skin is estimated at about 1% of that absorbed by the lungs when exposed to toluene vapor.

Dermal absorption is expected to be higher upon exposure to the liquid; however, exposure is limited by the rapid evaporation of toluene .

Distribution - In studies with mice exposed to radiolabeled toluene by inhalation, high levels of radioactivity were present in body fat, bone marrow, spinal nerves, spinal cord, and brain white matter. Lower levels of radioactivity were present in blood, kidney, and liver. Accumulation of toluene has generally been found in adipose tissue, other tissues with high fat content, and in highly vascularised tissues .

Metabolism - The metabolites of inhaled or ingested toluene include benzyl alcohol resulting from the hydroxylation of the methyl group. Further oxidation results in the formation of benzaldehyde and benzoic acid. The latter is conjugated with glycine to yield hippuric acid or reacted with glucuronic acid to form benzoyl glucuronide. o-cresol and p-cresol formed by ring hydroxylation are considered minor metabolites

Excretion - Toluene is primarily (60-70%) excreted through the urine as hippuric acid. The excretion of benzoyl glucuronide accounts for 10-20%, and excretion of unchanged toluene through the lungs also accounts for 10-20%. Excretion of hippuric acid is usually complete within 24 hours after exposure.

for full-range naphthas The CMR classification applies only to a raw material with Benzene = 0.1% w/w or Toluene = 3% w/w or n-hexane = 3% w/w. The CMR version of this substance is used in manufacture, distribution and as an intermediate. The CMR version of this substance is not used in widespread uses except as Professional Fuel and Consumer Fuel. The CMR version of this substance is also used in Formulation for Industrial Use in fuel.

The High Benzene Naphthas (HBNs; Lower Olefins and Aromatics -LOA - CAT H) Category was developed for the HPV Program by grouping ethylene manufacturing streams (products) that exhibit commonalities from both manufacturing process and compositional perspectives.

intermediates. The category includes hydrocarbon product streams associated with the ethylene industry that contain significant levels of benzene, generally with a benzene content greater than 10% and averaging about 55%. This grouping of CAS numbers represents hydrocarbon streams with a carbon number distribution that is predominantly C5- C11, through components boiling at 350 C or higher..

The high benzene naphthas category contains hydrocarbons (aliphatic, aromatic and olefinic) with carbon numbers predominantly in the C5-C10 range and boiling from approximately 30 deg C to 300 deg C. Members of this category contain >0.1% benzene and contain varying amounts of toluene, xylenes and n-hexane. Some category members contain naphthalenes, isoprene and 1,3-butadiene and this has been quantified where possible

All the streams in this category are complex UVCBs containing = 50% paraffins, = 60% isoparaffins, = 90% olefins, = 90% naphthenics, =100% aromatics, and above 0.1% benzene. All streams within this category are expected to have the following classifications H304, H315 and H336, H340, H350 (given their composition) and a flammability classification (either H224 or H226, depending on the flash point and / or the boiling point)

Benzene, as the predominant component in most streams, is expected to be the key driver with respect to health effects endpoints within the SIDS battery of tests. However, as the concentration of benzene is decreased and the concentrations of other components are increased, the observed effects of benzene are expected to diminish and the effects of other components are expected to increase.

The existing epidemiology and toxicology database for the components other than benzene and for mixtures containing the components is extensive. All components present in the streams at concentrations greater than 5% have been tested in at least one toxicity study. Those components having only limited data lack structural alerts for mammalian toxicity and data exist for their structural analogs. The C5 and C6 alkanes and alkenes present in the streams are not expected to significantly contribute to the toxicity profile as these substances are present in the streams at low concentrations and, with the exception of hexane, generally have a low level of toxicity. The toxic effects of hexane (present at < 15%) are unlikely to be observed due to the presence of the other components.

Genotoxicity: When tested as pure substances, some of the components other than benzene have caused genetic damage and adverse target organ effects in repeated-dose animal studies. When tested as pure substances, some of the components other than benzene have caused genetic damage and adverse target organ effects in repeated-dose animal studies. However, since the biologically active components of the High Benzene Naphthas streams are metabolized through a common P450 metabolic pathway, it is anticipated that multiple components will compete for the same active enzyme sites. Component toxicities, which are dependent on the formation of biologically active metabolites, may be reduced as less metabolite(s) will be produced through competition for these sites. Direct support for reduction or elimination of toxicities of individual components is provided by results of an existing mouse bone marrow micronucleus test with one of the High Benzene Naphthas streams, Hydrotreated C6-8 Fraction. This stream, containing approximately 55% benzene, was negative in a mouse bone marrow micronucleus test when administered by oral gavage at 5000 mg/kg to male and female CD-1 mice. Several studies have shown that benzene administered orally to CD-1 mice induces high frequencies of micronuclei in bone marrow erythrocytes at doses as low as 110 mg/kg . The presence in the Hydrotreated C6-8 Fraction of other components (approximately 25% toluene, 10% xylene, 7% pentane, 7% ethylbenzene, 3% cyclohexane, and 2% hexane) apparently inhibited the expected clastogenicity of benzene. Other similar interactions between components of the category have also been reported.

Repeat dose toxicity: Repeated oral or inhalation exposures to many of the components of the streams in the category have been shown to cause adverse health effects in a variety of organs. However, existing data also show that antagonistic and synergistic interactions occur between some components comprising the streams.

Developmental toxicity: Developmental toxicity data exist for most components present in this category at concentrations greater than 5% . In these studies, no convincing evidence was seen for teratogenicity in the absence of maternal toxicity. Foetotoxicity has been reported for some components, but mostly in the presence of maternal toxicity. A Pyrolysis

Gasoline Fraction stream similar to the Pyrolysis Gasoline streams in the HBNs Category has been tested in an oral developmental toxicity study in rabbits. No developmental effects were seen.

Reproductive toxicity: Some data for benzene indicates adverse gonadal effects (e.g., atrophy/degeneration, decrease in spermatozoa, moderate increases in abnormal sperm forms), data on reproductive outcomes are either inconclusive or conflicting. However, most studies indicate no effects on reproductive indices, even at high doses. Reproductive organ effects were seen after inhalation exposure to isoprene and hexane.

Gene Mutation: Of the identified category components present at concentrations greater than 5%, only 1,3-butadiene and benzene have consistently caused gene mutations in genetic toxicity tests . 1,3- Butadiene was positive in several *in vivo* and *in vitro* tests. Benzene was negative in several standard tests but was positive in an *in vivo* HPRT gene mutation test in mouse spleenocytes. Based on the data for components, the streams in the category are predicted to be negative in the HPV gene mutation test (Ames Test). Negative Ames Tests conducted with two streams (one from this category and one similar to category streams) support this prediction

NAPHTHA PETROLEUM, LIGHT SOLVENT-REFINED

UltraPly Bonding Adhesive

Chromosome Aberration:: Benzene has caused chromosome aberrations in *in vitro* and *in vivo* tests. The other most prevalent component in streams in this category, toluene, is negative in both *in vitro* and *in vivo* tests. Of the remaining identified category components present at concentrations greater than 5%, only vinyl acetate, 1,3-butadiene, isoprene, hexane, and naphthalene have been reported to cause chromosome aberrations.

For Low Boiling Point Naphthas (LBPNS):

Acute toxicity:

LBPNS generally have low acute toxicity by the oral (median lethal dose [LD50] in rats > 2000 mg/kg-bw), inhalation (LD50 in rats > 5000 mg/m³) and dermal (LD50 in rabbits > 2000 mg/kg-bw) routes of exposure

Most LBPNS are mild to moderate eye and skin irritants in rabbits, with the exception of heavy catalytic cracked and heavy catalytic reformed naphthas, which have higher primary skin irritation indices.

Sensitisation:

LBPNS do not appear to be skin sensitizers, but a poor response in the positive control was also noted in these studies

Repeat dose toxicity:

The lowest-observed-adverse-effect concentration (LOAEC) and lowest-observed-adverse-effect level (LOAEL) values identified following short-term (2-89 days) and subchronic (greater than 90 days) exposure to the LBPNS substances. These values were determined for a variety of endpoints after considering the toxicity data for all LBPNS in the group. Most of the studies were carried out by the inhalation route of exposure. Renal effects, including increased kidney weight, renal lesions (renal tubule dilation, necrosis) and hyaline droplet formation, observed in male rats exposed orally or by inhalation to most LBPNS, were considered species- and sex-specific. These effects were determined to be due to a mechanism of action not relevant to humans -specifically, the interaction between hydrocarbon metabolites and alpha-2-microglobulin, an enzyme not produced in substantial amounts in female rats, mice and other species, including humans. The resulting nephrotoxicity and subsequent carcinogenesis in male rats were therefore not considered in deriving LOAEC/LOAEL values.

Only a limited number of studies of short-term and subchronic duration were identified for site-restricted LBPNS. The lowest LOAEC identified in these studies, via the inhalation route, is 5475 mg/m³, based on a concentration-related increase in liver weight in both male and female rats following a 13-week exposure to light catalytic cracked naphtha. Shorter exposures of rats to this test substance resulted in nasal irritation at 9041 mg/m³

No systemic toxicity was reported following dermal exposure to light catalytic cracked naphtha, but skin irritation and accompanying histopathological changes were increased, in a dose-dependent manner, at doses as low as 30 mg/kg-bw per day when applied 5 days per week for 90 days in rats

No non-cancer chronic toxicity studies (= 1 year) were identified for site-restricted LBPNS and very few non-cancer chronic toxicity studies were identified for other LBPNS. An LOAEC of 200 mg/m³ was noted in a chronic inhalation study that exposed mice and rats to unleaded gasoline (containing 2% benzene). This inhalation LOAEC was based on ocular discharge and ocular irritation in rats. At the higher concentration of 6170 mg/m³, increased kidney weight was observed in male and female rats (increased kidney weight was also observed in males only at 870 mg/m³). Furthermore, decreased body weight in male and female mice was also observed at 6170 mg/m³

A LOAEL of 714 mg/kg-bw was identified for dermal exposure based on local skin effects (inflammatory and degenerative skin changes) in mice following application of naphtha for 105 weeks. No systemic toxicity was reported.

Genotoxicity:

Although few genotoxicity studies were identified for the site-restricted LBPNS, the genotoxicity of several other LBPNS substances has been evaluated using a variety of *in vivo* and *in vitro* assays. While *in vivo* genotoxicity assays were negative overall, the *in vitro* tests exhibited mixed results.

In vivo genotoxicity tests, LBPNS exhibited negative results for chromosomal aberrations and micronuclei induction, but exhibited positive results in one sister chromatid exchange assay although this result was not considered definitive for clastogenic activity as no genetic material was unbalanced or lost. Mixtures that were tested, which included a number of light naphthas, displayed mixed results (i.e., both positive and negative for the same assay) for chromosomal aberrations and negative results for the dominant lethal mutation assay. Unleaded gasoline (containing 2% benzene) was tested for its ability to induce unscheduled deoxyribonucleic acid (DNA) synthesis (UDS) and replicative DNA synthesis (RDS) in rodent hepatocytes and kidney cells. UDS and RDS were induced in mouse hepatocytes via oral exposure and RDS was induced in rat kidney cells via oral and inhalation exposure. Unleaded gasoline (benzene content not stated) exhibited negative results for chromosomal aberrations and the dominant lethal mutation assay and mixed results for atypical cell foci in rodent renal and hepatic cells.

In vitro genotoxicity studies, LBPNS were negative for six out of seven Ames tests, and were also negative for UDS and for forward mutations. LBPNS exhibited mixed or equivocal results for the mouse lymphoma and sister chromatid exchange assays, as well as for cell transformation and positive results for one bacterial DNA repair assay. Mixtures that were tested, which included a number of light naphthas, displayed negative results for the Ames and mouse lymphoma assays. Gasoline exhibited negative results for the Ames test battery, the sister chromatid exchange assay and for one mutagenicity assay. Mixed results were observed for UDS and the mouse lymphoma assay.

While the majority of *in vivo* genotoxicity results for LBPNS substances are negative, the potential for genotoxicity of LBPNS as a group cannot be discounted based on the mixed *in vitro* genotoxicity results.

Carcinogenicity:

Although a number of epidemiological studies have reported increases in the incidence of a variety of cancers, the majority of these studies are considered to contain incomplete or inadequate information. Limited data, however, are available for skin cancer and leukemia incidence, as well as mortality among petroleum refinery workers. It was concluded that there is limited evidence supporting the view that working in petroleum refineries entails a carcinogenic risk (Group 2A carcinogen). IARC (1989a) also classified gasoline as a Group 2B carcinogen; it considered the evidence for carcinogenicity in humans from gasoline to be inadequate and noted that published epidemiological studies had several limitations, including a lack of exposure data and the fact that it was not possible to separate the effects of combustion products from those of gasoline itself. Similar conclusions were drawn from other reviews of epidemiological studies for gasoline (US EPA 1987a, 1987b). Thus, the evidence gathered from these epidemiological studies is considered to be inadequate to conclude on the effects of human exposure to LBPNS substances.

No inhalation studies assessing the carcinogenicity of the site-restricted LBPNS were identified. Only unleaded gasoline has been examined for its carcinogenic potential, in several inhalation studies. In one study, rats and mice were exposed to 0, 200, 870 or 6170 mg/m³ of a 2% benzene formulation of the test substance, via inhalation, for approximately 2 years. A statistically significant increase in hepatocellular adenomas and carcinomas, as well as a non-statistical increase in renal tumours, were observed at the highest dose in female mice. A dose-dependent increase in the incidence of primary renal neoplasms was also detected in male rats, but this was not considered to be relevant to humans, as discussed previously. Carcinogenicity was also assessed for unleaded gasoline, via inhalation, as part of initiation/promotion studies. In these studies, unleaded gasoline did not appear to initiate tumour formation, but did show renal cell and hepatic tumour promotion ability, when rats and mice were exposed, via inhalation, for durations ranging from 13 weeks to approximately 1 year using an initiation/promotion protocol. However, further examination of data relevant to the composition of unleaded gasoline demonstrated that this is a highly-regulated substance; it is expected to contain a lower percentage of benzene and has a discrete component profile when compared to other substances in the LBPNS group.

Both the European Commission and the International Agency for Research on Cancer (IARC) have classified LBPNS substances as carcinogenic. All of these substances were classified by the European Commission (2008) as Category 2 (R45: may cause cancer) (benzene content = 0.1% by weight). IARC has classified gasoline, an LBPNS, as a Group 2B carcinogen (possibly carcinogenic to humans) and "occupational exposures in petroleum refining" as Group 2A carcinogens (probably carcinogenic to humans).

Several studies were conducted on experimental animals to investigate the dermal carcinogenicity of LBPNS. The majority of these studies were conducted through exposure of mice to doses ranging from 694-1351 mg/kg-bw, for durations ranging from 1 year to the animals' lifetime or until a tumour persisted for 2 weeks. Given the route of exposure, the studies specifically examined the formation of skin tumours. Results for carcinogenicity via dermal exposure are mixed. Both malignant and benign skin tumours were induced with heavy catalytic cracked naphtha, light catalytic cracked naphtha, light

straight-run naphtha and naphtha. Significant increases in squamous cell carcinomas were also observed when mice were dermally treated with Stoddard solvent, but the latter was administered as a mixture (90% test substance), and the details of the study were not available. In contrast, insignificant increases in tumour formation or no tumours were observed when light alkylate naphtha, heavy catalytic reformed naphtha, sweetened naphtha, light catalytically cracked naphtha

or unleaded gasoline was dermally applied to mice. Negative results for skin tumours were also observed in male mice dermally exposed to

sweetened naphtha using an initiation/promotion protocol.

Reproductive/ Developmental toxicity:

No reproductive or developmental toxicity was observed for the majority of LBP substances evaluated. Most of these studies were carried out by inhalation exposure in rodents.

NOAEC values for reproductive toxicity following inhalation exposure ranged from 1701 mg/m³ (CAS RN 8052-41-3) to 27 687 mg/m³ (CAS RN 64741-63-5) for the LBPNs group evaluated, and from 7690 mg/m³ to 27 059 mg/m³ for the site-restricted light catalytic cracked and full-range catalytic reformed naphthas. However, a decreased number of pups per litter and higher frequency of post-implantation loss were observed following inhalation exposure of female rats to hydrotreated heavy naphtha (CAS RN 64742-48-9) at a concentration of 4679 mg/m³, 6 hours per day, from gestational days 7-20. For dermal exposures, NOAEL values of 714 mg/kg-bw (CAS RN 8030-30-6) and 1000 mg/kg-bw per day (CAS RN 68513-02-0) were noted. For oral exposures, no adverse effects on reproductive parameters were reported when rats were given site-restricted light catalytic cracked naphtha at 2000 mg/kg on gestational day 13.

For most LBPNs, no treatment-related developmental effects were observed by the different routes of exposure. However, developmental toxicity was observed for a few naphthas. Decreased foetal body weight and an increased incidence of ossification variations were observed when rat dams were exposed to light aromatized solvent naphtha, by gavage, at 1250 mg/kg-bw per day. In addition, pregnant rats exposed by inhalation to hydrotreated heavy naphtha at 4679 mg/m³ delivered pups with higher birth weights. Cognitive and memory impairments were also observed in the offspring.

Low Boiling Point Naphthas [Site-Restricted]

For alkanes:

Exposure to the commercial hexane (a representative of the ECHA group of hydrocarbons, C5-C7, n-alkanes, isoalkanes, n-hexane rich) had no effect on the behavior of rats. Rats were tested monthly throughout the exposure for hindlimb splay and grip strength. The NOAEC for sub-chronic neurological effects is 9000 ppm in rats.

In a 13 week subchronic inhalation study, the neurotoxicity of light alkylate naphtha distillate (LAND-2; carbon range C5-C8) was examined in male and female rats and aside from acute CNS effects, no treatment related neurotoxic effects found in any of the treatment groups. The NOAEC was determined to be > 24.3 g/m³ (6646 ppm). Additionally, no neurological effects were reported in the NTP 2 year carcinogenicity study on Stoddard solvent.

For hydrocarbons, C5-C7, n-alkanes, isoalkanes, n-hexane rich

n-Hexane was metabolized and excreted within 168 h of iv bolus administration, inhalation exposure or dermal application. Exhaled breath and urine were the two primary routes for the excretion and its metabolites. n-Hexane was widely distributed to the body tissues but were not concentrated significantly by any of those tissues. It was extensively metabolized and a number of radio labeled metabolites were excreted in the urine. n-Hexane and its radio labeled metabolites disappeared from the blood of rats with a half-life of approximately 9-10 h.

Repeated inhalation exposure had no apparent effect on the rates or routes of excretion of either of the test compounds or their metabolites.

The absorption rates into the skin, normalised for exposure concentration, was determined to be 0.013 cm/h. The maximum absorption rate into the blood was determined to be 0.005 nmol/h. A comparison of the estimated whole-body skin uptake with the inhalatory uptake from the same atmosphere, revealed that the dermal uptake contributed 0.1% to the total uptake.

C9-C14 aliphatic, <2% aromatic hydrocarbon fluids are absorbed, they are typically metabolized by side chain oxidation to alcohol and carboxylic acid derivatives. These metabolites can be glucuronidated and excreted in the urine or further metabolized before being excreted. The majority of the metabolites are excreted in the urine and to a lower extent, in the faeces. Excretion is rapid with the majority of the elimination occurring within the first 24 hours of exposure. As a result of the lack of systemic toxicity and the ability of the parent material to undergo metabolism and rapid excretion, bioaccumulation of the test substance in the tissues is not likely to occur.

C9-C14 aliphatic, <2% aromatic hydrocarbon fluids are poorly absorbed dermally with an estimated overall percutaneous absorption rate of approximately 2µg/cm²/hr or 1% of the total applied fluid. Regardless of exposure route, C9-C14 aliphatic, <2% aromatic hydrocarbon fluids are rapidly metabolized and eliminated has been fully evaluated. All of the animal studies were performed in a manner similar or equivalent to currently established OECD guidelines. Based on these data, C9-C14 aliphatic, <2% aromatic hydrocarbons have a low order of acute toxicity by the oral, dermal, and inhalation routes of exposure.

In a study examining the oral toxicity of commercial hexane, 6 male rats were given doses of up to 25 ml/kg of test substance by oral gavage.

The animals were then observed for 14 days for mortality. No mortality was observed at any of the doses. The oral LD50 is therefore > 25 ml/kg (16.75 g/kg; density of 0.67).

C9-C14 aliphatic, <2% aromatic hydrocarbons is minimally toxic via ingestion where the LD50 is >5000 mg/kg, via dermal exposure where the LD50 is >5000 mg/kg, and by inhalation where the LC50 > 5000 mg/m³. These findings do not warrant classification of C9-C14 aliphatic, <2% aromatic hydrocarbons under the Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP) do not warrant classification under the Directive 67/548/EEC for dangerous substances and Directive 1999/45/EC for preparations (DSD/DPD). C9-C14 aliphatic, <2% aromatic hydrocarbons are classified under EU CLP guidelines as a Category 1 aspiration hazard based on its physical and chemical properties (hydrocarbon fluid, viscosity = 20.5 mm²/s) and as an R65 aspiration hazard under the EU DSD/DPD.

One study examined that acute inhalation toxicity of hexane to male rats. Groups of 10 male rats exposed to various large concentrations of hexane vapour for 4 hrs. Animals were then observed for clinical signs and mortality for at least the next 6 days. Several animals died during the exposure period. The LC50 was determined to be 73,680 ppm (259354 mg/m³). Due to the high concentration of the LC50, the test substance would not be classified as toxic by inhalation according to OECD GHS guidelines. Surviving animals experienced severe toxicological effects during the exposure.

Skin irritation:

For isoparaffinic, normal paraffinic, and mixed C9-C14 aliphatic, <2% aromatic hydrocarbon fluids, the weight of evidence indicates that the erythema and oedema scores (24, 48, and 72 average) are below the classification threshold requirements: 2.0, Directive 67/548/EEC for dangerous substances and Directive 1999/45/EC for preparation; 2.3, the new Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP).

For cycloparaffinic C9-C14 aliphatic, < 2% aromatic hydrocarbon fluids, erythema and oedema scores (24, 48, and 72 average) are above the classification threshold requirements: 2.0, Directive 67/518/EEC for dangerous substances and Directive 1999/45/EC for preparation; 2.3, the new Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP). This finding warrants classification of the test material as a skin irritant (R38) under Directive 67/518/EEC for dangerous substances and Directive 1999/45/EC for preparations. This finding warrants classification of the test material as a Category 2 dermal irritant under the new Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP).

Eye irritation

Ocular lesion scores (24, 48, and 72 average) are below the classification threshold requirements.

Directive 67/548/EEC for dangerous substances and Directive 1999/45/EC for preparation: 0, cornea opacity; 0, iris lesion; >2.5, redness of the conjunctivae; >2.0, oedema of the conjunctivae (chemosis). Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP): 0, cornea opacity; 0, iris lesion; >2.0, redness of the conjunctivae; >2.0, oedema of the conjunctivae (chemosis).

Respiratory irritation

There are no studies that warrant classification as a respiratory irritant under either the Directive 67/518/EEC for dangerous substances and Directive 1999/45/EC or under the new Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP).

Sensitisation:

A study was performed to determine the concentration of hexane that would be expected to cause sensitization in humans.

Results of previous LLNA experiments were used to calculate the EC3 value, the concentration at which the test substance would produce a 3 -fold increase in the proliferative activity of lymph nodes in the LLNA test. The 3 -fold increase is considered a positive response for sensitization in the LLNA test. The EC3 value for hexane was determined to be > 100% concentration. The test substance is therefore not sensitizing.

There are no reports of respiratory sensitization from C9-C14 aliphatic, <2% aromatic hydrocarbons fluids in laboratory animals or humans.

However, skin sensitization studies utilizing C9-C14 aliphatic, <2% aromatic hydrocarbons fluids found no indication of skin sensitization in guinea pigs. Additional studies in humans also found no indication of skin sensitization. With these observations, it is presumed that C9-C14 aliphatic, <2% aromatic hydrocarbons fluids will not be a respiratory sensitizing agent.

Repeat dose toxicity,

In a study involving n-hexane, neurological effects were only seen at the highest dose level after an average of 101.3 days of exposure. The

UltraPly Bonding Adhesive

LOAEL for neurological effects is 46.2 mmol/kg bw (37973 mg/kg), and the NOAEL is 13.2 mmol/kg bw (1135 mg/kg). Reduced body weight gain was seen at all three dose levels, however was only considered treatment related in the 13.2 and 46.2 mmol/kg bw groups. The NOAEL is therefore 6.60 mmol/kg bw.

In a study involving n-hexane The NOAEC for male rats exposed via inhalation was 2984 ppm based on liver and kidney effects. The LOAEC for male rats was 8992 ppm. The NOAEC for female rats was 8992 ppm

C9-C14 aliphatic, <2% aromatic hydrocarbon fluids are expected to have a low order of repeated dose toxicity by the oral route of exposure. All tests were performed in a manner similar or equivalent to currently established OECD guidelines. In a repeated dose study where C9-C14 aliphatic, <2% aromatic hydrocarbon fluids were administered via oral gavage, no signs of toxicity were observed at the maximum experimental dose tested, 5000 mg/kg/day.

In a repeated dose study where C9-C14 aliphatic, <2% aromatic hydrocarbon fluids were administered via inhalation, no signs of toxicity were observed at 10400 mg/m3. Based on these observations, the repeat inhalation concentration NOAEL is =10400 mg/m3 (10.4 mg/L) for C9-C14 aliphatic, <2% aromatic hydrocarbon fluid

Genetic toxicity:

A study examined the in vitro mutagenicity of vapours of the test substance commercial hexane. Plates of *S. typhimurium* were exposed for 7-8 hrs to test atmospheres of 0, 600, 1000, 3000, 6000, or 9000 ppm of test substance. The test substance did not produce a positive response in any of the test strains. The test substance is not mutagenic.

In a study to determine the in vivo effect of inhalation exposure of commercial hexane on rat bone marrow. Groups of 5 male and 5 female rats were exposed to 0, 900, 3000, and 9000 ppm of test substance vapour for 6 hrs/day for 5 days. There was no statistically significant increase in cell aberrations in any treatment group. The test substance is not mutagenic.

C9-C14 aliphatic, <2% aromatic hydrocarbons fluids are not mutagenic using in vitro or in vivo genotoxicity assays. In bacterial tests, C9-C14 aliphatic, <2% aromatic hydrocarbons fluids were not mutagenic in *Salmonella* strains tested in the presence or absence of metabolic activation.

C9-C14 aliphatic, <2% aromatic hydrocarbon fluids were negative in a in vitro mammalian cell gene mutation assay. In sister chromatid exchange and in chromosomal aberration studies, C9-C14 aliphatic, <2% aromatic hydrocarbons fluids did not produce an effect. C9-C14 aliphatic, <2% aromatic hydrocarbons fluids were also non-mutagenic when tested in an in vivo mouse bone marrow micronucleus assay and when tested in dominant lethal studies utilizing an inhalation route of exposure. All studies were conducted in a manner similar or equivalent to currently established OECD guidelines. C9-C14 aliphatic, <2% aromatic hydrocarbons fluids are a non-genotoxic agent and classification is not warranted under the Regulation (EC) 1272/2008 on classification, labeling and packaging of substances and mixtures (CLP) or under the Directive 67/518/EEC for dangerous substances and Directive 1999/45/EC for preparations.

Toxicity to reproduction.

In a study examining the effects of commercial hexane the NOAEC for both male and female rats (adults and offspring) was 3000 ppm (10560 mg/m3). The LOAEC for these groups was 9000 ppm based on reduced body weight. There were no adverse effects to reproduction, therefore the NOAEC for reproduction is 9000 ppm (31680 mg/m3).

A study to examine the developmental toxicity of commercial hexane in mice, found the maternal NOAEC was 900 ppm, and the maternal LOAEC was 3000 ppm (10560 mg/m3) based on colour changes in the lungs. The developmental NOAEC was 3000 ppm and the LOAEC was 9000 ppm (31680 mg/m3) in mice.

C9-C14 aliphatic, <2% aromatic hydrocarbon fluids are not developmental toxicants. In two developmental studies (OECD TG 414), pregnant dams were dosed by inhalation with 0, 300, or 900 ppm C9-C14 aliphatic, <2% aromatic hydrocarbon fluids during gestational days 6 through 15. No adverse maternal or fetal effects were noted at any dose level. Thus, C9-C14 aliphatic, <2% aromatic hydrocarbon fluids did not produce any maternal or fetal toxicity or any developmental effects in rats. Based on the study results, the maternal and developmental toxicity NOAEC is >= 900 ppm (5220 mg/m3). Based on this study and the lack of systemic toxicity, C9-C14 aliphatic, <2% aromatic hydrocarbon fluids, are not expected to be developmental toxicants.

Data demonstrate that during inhalation exposure, aromatic hydrocarbons undergo substantial partitioning into adipose tissues. Following cessation of exposure, the level of aromatic hydrocarbons in body fats rapidly declines. Thus, the aromatic hydrocarbons are unlikely to bioaccumulate in the body. Selective partitioning of the aromatic hydrocarbons into the non-adipose tissues is unlikely. No data is available regarding distribution following dermal absorption. However, distribution following this route of exposure is likely to resemble the pattern occurring with inhalation exposure.

Aromatics hydrocarbons may undergo several different Phase I dealkylation, hydroxylation and oxidation reactions which may or may not be followed by Phase II conjugation to glycine, sulfation or glucuronidation. However, the major predominant biotransformation pathway is typical of that of the alkylbenzenes and consists of: (1) oxidation of one of the alkyl groups to an alcohol moiety; (2) oxidation of the hydroxyl group to a carboxylic acid; (3) the carboxylic acid is then conjugated with glycine to form a hippuric acid. The minor metabolites can be expected to consist of a complex mixture of isomeric triphenols, the sulfate and glucuronide conjugates of dimethylbenzyl alcohols, dimethylbenzoic acids and dimethylhippuric acids. Consistent with the low propensity for bioaccumulation of aromatic hydrocarbons, these substances are likely to be significant inducers of their own metabolism.

The predominant route of excretion of aromatic hydrocarbons following inhalation exposure involves either exhalation of the unmetabolized parent compound, or urinary excretion of its metabolites. When oral administration occurs, there is little exhalation of unmetabolized these hydrocarbons, presumably due to the first pass effect in the liver. Under these circumstances, urinary excretion of metabolites is the dominant route of excretion.

Studies indicate that normal, branched and cyclic paraffins are absorbed from the mammalian gastrointestinal tract and that the absorption of n-paraffins is inversely proportional to the carbon chain length, with little absorption above C30. With respect to the carbon chain lengths likely to be present in mineral oil, n-paraffins may be absorbed to a greater extent than iso- or cyclo-paraffins.

The major classes of hydrocarbons have been shown to be well absorbed by the gastrointestinal tract in various species. In many cases, the hydrophobic hydrocarbons are ingested in association with dietary lipids. The dependence of hydrocarbon absorption on concomitant triglyceride digestion and absorption, is known as the "hydrocarbon continuum hypothesis", and asserts that a series of solubilising phases in the intestinal lumen, created by dietary triglycerides and their digestion products, afford hydrocarbons a route to the lipid phase of the intestinal absorptive cell (enterocyte) membrane. While some hydrocarbons may traverse the mucosal epithelium unmetabolized and appear as solutes in lipoprotein particles in intestinal lymph, there is evidence that most hydrocarbons partially separate from nutrient lipids and undergo metabolic transformation in the enterocyte. The enterocyte may play a major role in determining the proportion of an absorbed hydrocarbon that, by escaping initial biotransformation, becomes available for deposition in its unchanged form in peripheral tissues such as adipose tissue, or in the liver.

For trimethylbenzenes:

Absorption of 1,2,4-trimethylbenzene occurs after oral, inhalation, or dermal exposure. Occupationally, inhalation and dermal exposures are the most important routes of absorption although systemic intoxication from dermal absorption is not likely to occur due to the dermal irritation caused by the chemical prompting quick removal. Following oral administration of the chemical to rats, 62.6% of the dose was recovered as urinary metabolites indicating substantial absorption. 1,2,4-Trimethylbenzene is lipophilic and may accumulate in fat and fatty tissues. In the blood stream, approximately 85% of the chemical is bound to red blood cells. Metabolism occurs by side-chain oxidation to form alcohols and carboxylic acids which are then conjugated with glucuronic acid, glycine, or sulfates for urinary excretion. After a single oral dose to rats of 1200 mg/kg, urinary metabolites consisted of approximately 43.2% glycine, 6.6% glucuronic, and 12.9% sulfuric acid conjugates. The two principle metabolites excreted by rabbits after oral administration of 438 mg/kg/day for 5 days were 2,4-dimethylbenzoic acid and 3,4-dimethylhippuric acid. The major routes of excretion of 1,2,4-trimethylbenzene are exhalation of parent compound and elimination of urinary metabolites. Half-times for urinary metabolites were reported as 9.5 hours for glycine, 22.9 hours for glucuronide, and 37.6 hours for sulfuric acid conjugates.

Acute Toxicity Direct contact with liquid 1,2,4-trimethylbenzene is irritating to the skin and breathing the vapor is irritating to the respiratory tract causing pneumonitis. Breathing high concentrations of the chemical vapor causes headache, fatigue, and drowsiness. In humans liquid 1,2,4-trimethylbenzene is irritating to the skin and inhalation of vapor causes chemical pneumonitis. High concentrations of vapor (5000-9000 ppm) cause headache, fatigue, and drowsiness. The concentration of 5000 ppm is roughly equivalent to a total of 221 mg/kg assuming a 30 minute exposure period (see end note 1). 2. Animals - Mice exposed to 8130-9140 ppm 1,2,4-trimethylbenzene (no duration given) had loss of righting response and loss of reflexes. Direct dermal contact with the chemical (no species given) causes vasodilation, erythema, and irritation (U.S. EPA). Seven of 10 rats died after an oral dose of 2.5 mL of a mixture of trimethylbenzenes in olive oil (average dose approximately 4.4 g/kg). Rats and mice were exposed by inhalation to a coal tar distillate containing about 70% 1,3,5- and 1,2,4-trimethylbenzene; no pathological changes were noted in either species after exposure to 1800-2000 ppm for up to 48 continuous hours, or in rats after 14 exposures of 8 hours each at the

UltraPly Bonding Adhesive

same exposure levels. No effects were reported for rats exposed to a mixture of trimethyl- benzenes at 1700 ppm for 10 to 21 days

Neurotoxicity 1,2,4-Trimethylbenzene depresses the central nervous system. Exposure to solvent mixtures containing the chemical causes headache, fatigue, nervousness, and drowsiness. Occupationally, workers exposed to a solvent containing 50% 1,2,4-trimethylbenzene had nervousness, headaches, drowsiness, and vertigo (U.S. EPA). Headache, fatigue, and drowsiness were reported for workers exposed (no dose given) to paint thinner containing 80% 1,2,4- and 1,3,5-trimethylbenzenes

Results of the developmental toxicity study indicate that the C9 fraction caused adverse neurological effects at the highest dose (1500 ppm) tested.

Subchronic/Chronic Toxicity Long-term exposure to solvents containing 1,2,4-trimethylbenzene may cause nervousness, tension, and bronchitis. Painters that worked for several years with a solvent containing 50% 1,2,4- and 30% 1,3,5-trimethylbenzene showed nervousness, tension and anxiety, asthmatic bronchitis, anemia, and alterations in blood clotting; haematological effects may have been due to trace amounts of benzene

Rats given 1,2,4-trimethylbenzene orally at doses of 0.5 or 2.0 g/kg/day, 5 days/week for 4 weeks. All rats exposed to the high dose died and 1 rat in the low dose died (no times given); no other effects were reported. Rats exposed by inhalation to 1700 ppm of a trimethylbenzene isomeric mixture for 4 months had decreased weight gain, lymphopenia and neutrophilia .

Genotoxicity: Results of mutagenicity testing, indicate that the C9 fraction does not induce gene mutations in prokaryotes (Salmonella typhimurium/mammalian microsome assay); or in mammalian cells in culture (in Chinese hamster ovary cells with and without activation). The C9 fraction does not induce chromosome mutations in Chinese hamster ovary cells with and without activation; does not induce chromosome aberrations in the bone marrow of Sprague-Dawley rats exposed by inhalation (6 hours/day for 5 days); and does not induce sister chromatid exchange in Chinese hamster ovary cells with and without activation.

Developmental/Reproductive Toxicity: A three-generation reproductive study on the C9 fraction was conducted. CD rats (30/sex/group) were exposed by inhalation to the C9 fraction at concentrations of 0, 100, 500, or 1500 ppm (0, 100, 500, or 1500 mg/kg/day) for 6 hours/day, 5 days/week. There was evidence of parental and reproductive toxicity at all dose levels. Indicators of parental toxicity included reduced body weights, increased salivation, hunched posture, aggressive behavior, and death. Indicators of adverse reproductive system effects included reduced litter size and reduced pup body weight. The LOEL was 100 ppm; a no-observed-effect level was not established. Developmental toxicity, including possible developmental neurotoxicity, was evident in rats in a 3-generation reproductive study

No effects on fecundity or fertility occurred in rats treated dermally with up to 0.3 mL/rat/day of a mixture of trimethyl- benzenes, 4-6 hours/day, 5 days/week over one generation

Chronic inhalation exposures may show indications of peripheral neuropathy, a progressive nerve disorder of extremities.

For C9 aromatics (typically trimethylbenzenes - TMBs)

Acute Toxicity

Acute toxicity studies (oral, dermal and inhalation routes of exposure) have been conducted in rats using various solvent products containing predominantly mixed C9 aromatic hydrocarbons (CAS RN 64742-95-6). Inhalation LC50's range from 6,000 to 10,000 mg/m³ for C9 aromatic naphtha and 18,000 to 24,000 mg/m³ for 1,2,4 and 1,3,5-TMB, respectively. A rat oral LD50 reported for 1,2,4-TMB is 5 grams/kg bw and a rat dermal LD50 for the C9 aromatic naphtha is >4 mL/kg bw. These data indicate that C9 aromatic solvents show that LD50/LC50 values are greater than limit doses for acute toxicity studies established under OECD test guidelines.

Irritation and Sensitization

Several irritation studies, including skin, eye, and lung/respiratory system, have been conducted on members of the category. The results indicate that C9 aromatic hydrocarbon solvents are mildly to moderately irritating to the skin, minimally irritating to the eye, and have the potential to irritate the respiratory tract and cause depression of respiratory rates in mice. Respiratory irritation is a key endpoint in the current occupational exposure limits established for C9 aromatic hydrocarbon solvents and trimethylbenzenes. No evidence of skin sensitization was identified.

Repeated Dose Toxicity

Inhalation: The results from a subchronic (3 month) neurotoxicity study and a one-year chronic study (6 hr/day, 5 days/week) indicate that effects from inhalation exposure to C9 Aromatic Hydrocarbon Solvents on systemic toxicity are slight. A battery of neurotoxicity and neurobehavioral endpoints were evaluated in the 3-month inhalation study on C9 aromatic naphtha tested at concentrations of 0, 101, 452, or 1320 ppm (0, 500, 2,220, or 6,500 mg/m³). In this study, other than a transient weight reduction in the high exposure group (not statistically significant at termination of exposures), no effects were reported on neuropathology or neuro/behavioral parameters. The NOAEL for systemic and/or neurotoxicity was 6,500 mg/m³, the highest concentration tested. In an inhalation study of a commercial blend, rats were exposed to C9 aromatic naphtha concentrations of 0, 96, 198, or 373 ppm (0, 470, 970, 1830 mg/m³) for 6 hr/day, 5 days/week, for 12 months. Liver and kidney weights were increased in the high exposure group but no accompanying histopathology was observed in these organs.

The NOAEL was considered to be the high exposure level of 373 ppm, or 1830 mg/m³. In two subchronic rat inhalation studies, both of three months duration, rats were exposed to the individual TMB isomers (1,2,4- and 1,3,5-) to nominal concentrations of 0, 25, 100, or 250 ppm (0, 123, 492, or 1230 mg/m³). Respiratory irritation was observed at 492 (100 ppm) and 1230 mg/m³ (250 ppm) and no systemic toxicity was observed in either study. For both pure isomers, the NOELs are 25 ppm or 123 mg/m³ for respiratory irritation and 250 ppm or 1230 mg/m³ for systemic effects.

Oral: The C9 aromatic naphtha has not been tested via the oral route of exposure. Individual TMB isomers have been evaluated in a series of repeated-dose oral studies ranging from 14 days to 3 months over a wide range of doses. The effects observed in these studies included increased liver and kidney weights, changes in blood chemistry, increased salivation, and decreased weight gain at higher doses. Organ weight changes appeared to be adaptive as they were not accompanied by histopathological effects. Blood changes appeared sporadic and without pattern. One study reported hyaline droplet nephropathy in male rats at the highest dose (1000 mg/kg bw-day), an effect that is often associated with alpha-2mu-globulin-induced nephropathy and not considered relevant to humans. The doses at which effects were detected were 100 mg/kg-bw day or above (an exception was the pilot 14 day oral study - LOAEL 150 mg/kg bw-day - but the follow up three month study had a LOAEL of 600 mg/kg/bw-day with a NOAEL of 200 mg/kg bw-day). Since effects generally were not severe and could be considered adaptive or spurious, oral exposure does not appear to pose a high toxicity hazard for pure trimethylbenzene isomers.

Mutagenicity

In vitro genotoxicity testing of a variety of C9 aromatics has been conducted in both bacterial and mammalian cells. In vitro point mutation tests were conducted with Salmonella typhimurium and Escherichia coli bacterial strains, as well as with cultured mammalian cells such as the Chinese hamster cell ovary cells (HGPRT assay) with and without metabolic activation. In addition, several types of in vitro chromosomal aberration tests have been performed (chromosome aberration frequency in Chinese hamster ovary and lung cells, sister chromatid exchange in CHO cells). Results were negative both with and without metabolic activation for all category members. For the supporting chemical 1,2,3-TMB, a single in vitro chromosome aberration test was weakly positive. In vivo bone marrow cytogenetics test, rats were exposed to C9 aromatic naphtha at concentrations of 0, 153, 471, or 1540 ppm (0, 750, 2,310, or 7,560 mg/m³) 6 hr/day, for 5 days. No evidence of in vivo somatic cell genotoxicity was detected. Based on the cumulative results of these assays, genetic toxicity is unlikely for substances in the C9 Aromatic Hydrocarbon Solvents Category

Reproductive and Developmental Toxicity

Results from the three-generation reproduction inhalation study in rats indicate limited effects from C9 aromatic naphtha. In each of three generations (F0, F1 and F2), rats were exposed to High Flash Aromatic Naphtha (CAS RN 64742-95-6) via whole body inhalation at target concentrations of 0, 100, 500, or 1500 ppm (actual mean concentrations throughout the full study period were 0, 103, 495, or 1480 ppm, equivalent to 0, 505, 2430, or 7265 mg/m³, respectively). In each generation, both sexes were exposed for 10 weeks prior to and two weeks during mating for 6 hrs/day, 5 days/wks. Female rats in the F0, F1, and F2 generation were then exposed during gestation days 0-20 and lactation days 5-21 for 6 hrs/day, 7 days/wk. The age at exposure initiation differed among generations; F0 rats were exposed starting at 9 weeks of age, F1 exposure began at 5-7 weeks, and F2 exposure began at postnatal day (PND) 22. In the F0 and F1 parental generations, 30 rats/sex/group were exposed and mated. However, in the F2 generation, 40/sex/group were initially exposed due to concerns for toxicity, and 30/sex/group were randomly selected for mating, except that all survivors were used at 1480 ppm. F3 litters were not exposed directly and were sacrificed on lactation day 21.

Systemic Effects on Parental Generations:

The F0 males showed statistically and biologically significantly decreased mean body weight by ~15% at 1480 ppm when compared with controls. Seven females died or were sacrificed in extremis at 1480 ppm. The F0 female rats in the 495 ppm exposed group had a 13% decrease in body weight gain when adjusted for initial body weight when compared to controls. The F1 parents at 1480 ppm had statistically significantly

decreased mean body weights (by ~13% (females) and 22% (males)), and locomotor activity. F1 parents at 1480 ppm had increased ataxia and mortality (six females). Most F2 parents (70/80) exposed to 1480 ppm died within the first week. The remaining animals survived throughout the rest of the exposure period. At week 4 and continuing through the study, F2 parents at 1480 ppm had statistically significant mean body weights much lower than controls (~33% for males; ~28% for females); body weights at 495 ppm were also reduced significantly (by 13% in males and 15% in females). The male rats in the 495 ppm exposed group had a 12% decrease in body weight gain when adjusted for initial body weight when compared to controls. Based on reduced body weight observed, the overall systemic toxicity LOAEC is 495 ppm (2430 mg/m³).

Reproductive Toxicity-Effects on Parental Generations: There were no pathological changes noted in the reproductive organs of any animal of the F0, F1, or F2 generation. No effects were reported on sperm morphology, gestational period, number of implantation sites, or post-implantation loss in any generation. Also, there were no statistically or biologically significant differences in any of the reproductive parameters, including: number of mated females, copulatory index, copulatory interval, number of females delivering a litter, number of females delivering a live litter, or male fertility in the F0 or in the F2 generation. Male fertility was statistically significantly reduced at 1480 ppm in the F1 rats. However, male fertility was not affected in the F0 or in the F2 generations; therefore, the biological significance of this change is unknown and may or may not be attributed to the test substance. No reproductive effects were observed in the F0 or F1 dams exposed to 1480 ppm (7265 mg/m³). Due to excessive mortality at the highest concentration (1480 ppm, only six dams available) in the F2 generation, a complete evaluation is precluded. However, no clear signs of reproductive toxicity were observed in the F2 generation. Therefore, the reproductive NOAEC is considered 495 ppm (2430 mg/m³), which excludes analysis of the highest concentration due to excessive mortality.

Developmental Toxicity - Effects on Pups: Because of significant maternal toxicity (including mortality) in dams in all generations at the highest concentration (1480 ppm), effects in offspring at 1480 ppm are not reported here. No significant effects were observed in the F1 and F2 generation offspring at 103 or 495 ppm. However, in F3 offspring, body weights and body weight gain were reduced by ~ 10-11% compared with controls at 495 ppm for approximately a week (PND 14 through 21). Maternal body weight was also depressed by ~ 12% throughout the gestational period compared with controls. The overall developmental LOAEC from this study is 495 ppm (2430 mg/m³) based on the body weights reductions observed in the F3 offspring.

Conclusion: No effects on reproductive parameters were observed at any exposure concentration, although a confident assessment of the group exposed at the highest concentration was not possible. A potential developmental effect (reduction in mean pup weight and weight gain) was observed at a concentration that was also associated with maternal toxicity.

WARNING: This substance has been classified by the IARC as Group 1: **CARCINOGENIC TO HUMANS.**

for petroleum:

Altered mental state, drowsiness, peripheral motor neuropathy, irreversible brain damage (so-called Petrol Sniffer's Encephalopathy), delirium, seizures, and sudden death have been reported from repeated overexposure to some hydrocarbon solvents, naphthas, and gasoline

This product may contain benzene which is known to cause acute myeloid leukaemia and n-hexane which has been shown to metabolize to compounds which are neuropathic.

This product contains toluene. There are indications from animal studies that prolonged exposure to high concentrations of toluene may lead to hearing loss.

This product contains ethyl benzene and naphthalene from which there is evidence of tumours in rodents

Carcinogenicity: Inhalation exposure to mice causes liver tumours, which are not considered relevant to humans. Inhalation exposure to rats causes kidney tumours which are not considered relevant to humans.

Mutagenicity: There is a large database of mutagenicity studies on gasoline and gasoline blending streams, which use a wide variety of endpoints and give predominantly negative results. All in vivo studies in animals and recent studies in exposed humans (e.g. petrol service station attendants) have shown negative results in mutagenicity assays.

Reproductive Toxicity: Repeated exposure of pregnant rats to high concentrations of toluene (around or exceeding 1000 ppm) can cause developmental effects, such as lower birth weight and developmental neurotoxicity, on the foetus. However, in a two-generation reproductive study in rats exposed to gasoline vapour condensate, no adverse effects on the foetus were observed.

Human Effects: Prolonged/ repeated contact may cause defatting of the skin which can lead to dermatitis and may make the skin more susceptible to irritation and penetration by other materials.

Lifetime exposure of rodents to gasoline produces carcinogenicity although the relevance to humans has been questioned. Gasoline induces kidney cancer in male rats as a consequence of accumulation of the alpha2-microglobulin protein in hyaline droplets in the male (but not female) rat kidney. Such abnormal accumulation represents lysosomal overload and leads to chronic renal tubular cell degeneration, accumulation of cell debris, mineralisation of renal medullary tubules and necrosis. A sustained regenerative proliferation occurs in epithelial cells with subsequent neoplastic transformation with continued exposure. The alpha2-microglobulin is produced under the influence of hormonal controls in male rats but not in females and, more importantly, not in humans.

* REACH Dossier

ACETONE

for acetone:

The acute toxicity of acetone is low. Acetone is not a skin irritant or sensitiser but is a defatting agent to the skin. Acetone is an eye irritant. The subchronic toxicity of acetone has been examined in mice and rats that were administered acetone in the drinking water and again in rats treated by oral gavage. Acetone-induced increases in relative kidney weight changes were observed in male and female rats used in the oral 13-week study. Acetone treatment caused increases in the relative liver weight in male and female rats that were not associated with histopathological effects and the effects may have been associated with microsomal enzyme induction. Haematologic effects consistent with macrocytic anaemia were also noted in male rats along with hyperpigmentation in the spleen. The most notable findings in the mice were increased liver and decreased spleen weights. Overall, the no-observed-effect-levels in the drinking water study were 1% for male rats (900 mg/kg/d) and male mice (2258 mg/kg/d), 2% for female mice (5945 mg/kg/d), and 5% for female rats (3100 mg/kg/d). For developmental effects, a statistically significant reduction in foetal weight, and a slight, but statistically significant increase in the percent incidence of later resorptions were seen in mice at 15,665 mg/m³ and in rats at 26,100 mg/m³. The no-observable-effect level for developmental toxicity was determined to be 5220 mg/m³ for both rats and mice.

Teratogenic effects were not observed in rats and mice tested at 26,110 and 15,665 mg/m³, respectively. Lifetime dermal carcinogenicity studies in mice treated with up to 0.2 mL of acetone did not reveal any increase in organ tumor incidence relative to untreated control animals.

The scientific literature contains many different studies that have measured either the neurobehavioural performance or neurophysiological response of humans exposed to acetone. Effect levels ranging from about 600 to greater than 2375 mg/m³ have been reported. Neurobehavioral studies with acetone-exposed employees have recently shown that 8-hr exposures in excess of 2375 mg/m³ were not associated with any dose-related changes in response time, vigilance, or digit span scores. Clinical case studies, controlled human volunteer studies, animal research, and occupational field evaluations all indicate that the NOAEL for this effect is 2375 mg/m³ or greater.

XYLENE

Reproductive effector in rats

The material may produce severe irritation to the eye causing pronounced inflammation. Repeated or prolonged exposure to irritants may produce conjunctivitis.

STYRENE

WARNING: This substance has been classified by the IARC as Group 2B: Possibly Carcinogenic to Humans.

MAGNESIUM OXIDE

The following information refers to contact allergens as a group and may not be specific to this product.

Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

Asthma-like symptoms may continue for months or even years after exposure to the material ceases. This may be due to a non-allergenic

	condition known as reactive airways dysfunction syndrome (RADS) which can occur following exposure to high levels of highly irritating compound. Key criteria for the diagnosis of RADS include the absence of preceding respiratory disease, in a non-atopic individual, with abrupt onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. A reversible airflow pattern, on spirometry, with the presence of moderate to severe bronchial hyperreactivity on methacholine challenge testing and the lack of minimal lymphocytic inflammation, without eosinophilia, have also been included in the criteria for diagnosis of RADS. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. Industrial bronchitis, on the other hand, is a disorder that occurs as result of exposure due to high concentrations of irritating substance (often particulate in nature) and is completely reversible after exposure ceases. The disorder is characterised by dyspnea, cough and mucus production.
TOLUENE & XYLENE & STYRENE	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling the epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.
CHLOROPRENE HOMOPOLYMER & XYLENE	The substance is classified by IARC as Group 3: NOT classifiable as to its carcinogenicity to humans. Evidence of carcinogenicity may be inadequate or limited in animal testing.
ACETONE & ZINC OXIDE	The material may cause skin irritation after prolonged or repeated exposure and may produce a contact dermatitis (nonallergic). This form of dermatitis is often characterised by skin redness (erythema) and swelling epidermis. Histologically there may be intercellular oedema of the spongy layer (spongiosis) and intracellular oedema of the epidermis.

Acute Toxicity	✓	Carcinogenicity	✓
Skin Irritation/Corrosion	✓	Reproductivity	✓
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	✓
Respiratory or Skin sensitisation	✓	STOT - Repeated Exposure	✓
Mutagenicity	✗	Aspiration Hazard	✓

Legend: ✗ – Data either not available or does not fill the criteria for classification
 ✓ – Data available to make classification

SECTION 12 Ecological information

Toxicity

	Endpoint	Test Duration (hr)	Species	Value	Source
UltraPly Bonding Adhesive	Not Available	Not Available	Not Available	Not Available	Not Available
toluene	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	168h	Crustacea	0.74mg/L	5
	LC50	96h	Fish	5-35mg/l	4
	EC50	48h	Crustacea	3.78mg/L	5
naphtha petroleum, light solvent-refined	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	72h	Algae or other aquatic plants	<0.1mg/l	1
	LC50	96h	Fish	1mg/l	2
	EC50	72h	Algae or other aquatic plants	6.5mg/l	1
	EC50	48h	Crustacea	0.9mg/l	2
acetone	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	12h	Fish	0.001mg/L	4
	LC50	96h	Fish	3744.6-5000.7mg/L	4
	EC50	48h	Crustacea	6098.4mg/L	5
	EC50	96h	Algae or other aquatic plants	9.873-27.684mg/l	4
xylylene	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	73h	Algae or other aquatic plants	0.44mg/l	2
	LC50	96h	Fish	2.6mg/l	2
	EC50	72h	Algae or other aquatic plants	4.6mg/l	2
styrene	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	96h	Algae or other aquatic plants	0.063mg/l	1
styrene	Endpoint	Test Duration (hr)	Species	Value	Source
	LC50	96h	Fish	4.02mg/l	2

	EC50	72h	Algae or other aquatic plants	1.4mg/l	1
	EC50	48h	Crustacea	4.7mg/l	1
	EC50	96h	Algae or other aquatic plants	0.72mg/l	1
magnesium oxide	Endpoint	Test Duration (hr)	Species	Value	Source
	Not Available	Not Available	Not Available	Not Available	Not Available
zinc oxide	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	72h	Algae or other aquatic plants	0.005mg/l	2
	BCF	1344h	Fish	19-110	7
	LC50	96h	Fish	0.927-2.589mg/l	4
	EC50	72h	Algae or other aquatic plants	0.036-0.049mg/l	4
	EC50	48h	Crustacea	0.301-0.667mg/l	4
	EC50	96h	Algae or other aquatic plants	0.3mg/l	2
Legend:	Extracted from 1. IUCLID Toxicity Data 2. Europe ECHA Registered Substances - Ecotoxicological Information - Aquatic Toxicity 3. EPIWIN Suite V3.12 (QSAR) - Aquatic Toxicity Data (Estimated) 4. US EPA, Ecotox database - Aquatic Toxicity Data 5. ECETOC Aquatic Hazard Assessment Data 6. NITE (Japan) - Bioconcentration Data 7. METI (Japan) - Bioconcentration Data 8. Vendor Data				

Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air
toluene	LOW (Half-life = 28 days)	LOW (Half-life = 4.33 days)
chloroprene homopolymer	HIGH	HIGH
acetone	LOW (Half-life = 14 days)	MEDIUM (Half-life = 116.25 days)
xylene	HIGH (Half-life = 360 days)	LOW (Half-life = 1.83 days)
styrene	HIGH (Half-life = 210 days)	LOW (Half-life = 0.3 days)

Bioaccumulative potential

Ingredient	Bioaccumulation
toluene	LOW (BCF = 90)
chloroprene homopolymer	LOW (LogKOW = 2.5253)
acetone	LOW (BCF = 0.69)
xylene	MEDIUM (BCF = 740)
styrene	LOW (BCF = 77)
zinc oxide	LOW (BCF = 217)

Mobility in soil

Ingredient	Mobility
toluene	LOW (KOC = 268)
chloroprene homopolymer	LOW (KOC = 67.7)
acetone	HIGH (KOC = 1.981)
styrene	LOW (KOC = 517.8)

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal	<ul style="list-style-type: none"> ▶ Containers may still present a chemical hazard/ danger when empty. ▶ Return to supplier for reuse/ recycling if possible. <p>Otherwise:</p> <ul style="list-style-type: none"> ▶ If container can not be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill. ▶ Where possible retain label warnings and SDS and observe all notices pertaining to the product. ▶ DO NOT allow wash water from cleaning or process equipment to enter drains. ▶ It may be necessary to collect all wash water for treatment before disposal. ▶ In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first. ▶ Where in doubt contact the responsible authority. ▶ Recycle wherever possible. ▶ Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified. ▶ Dispose of by: burial in a land-fill specifically licensed to accept chemical and / or pharmaceutical wastes or Incineration in a licensed apparatus (after admixture with suitable combustible material). ▶ Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.
-------------------------------------	---

Ensure that the hazardous substance is disposed in accordance with the Hazardous Substances (Disposal) Notice 2017

Continued...

Disposal Requirements

Packages that have been in direct contact with the hazardous substance must be only disposed if the hazardous substance was appropriately removed and cleaned out from the package. The package must be disposed according to the manufacturer's directions taking into account the material it is made of. Packages which hazardous content have been appropriately treated and removed may be recycled.

The hazardous substance must only be disposed if it has been treated by a method that changed the characteristics or composition of the substance and it is no longer hazardous. DO NOT deposit the hazardous substance into or onto a landfill or a sewage facility.

Burning the hazardous substance must happen under controlled conditions with no person or place exposed to

(1) a blast overpressure of more than 9 kPa; or

(2) an unsafe level of heat radiation.

The disposed hazardous substance must not come into contact with class 1 or 5 substances.

SECTION 14 Transport information**Labels Required**

	
Marine Pollutant	NO
HAZCHEM	*3YE

Land transport (UN)

UN number	1133	
UN proper shipping name	ADHESIVES containing flammable liquid	
Transport hazard class(es)	Class	3
	Subrisk	Not Applicable
Packing group	II	
Environmental hazard	Not Applicable	
Special precautions for user	Special provisions	Not Applicable
	Limited quantity	5 L

Air transport (ICAO-IATA / DGR)

UN number	1133	
UN proper shipping name	Adhesives containing flammable liquid	
Transport hazard class(es)	ICAO/IATA Class	3
	ICAO / IATA Subrisk	Not Applicable
	ERG Code	3L
Packing group	II	
Environmental hazard	Not Applicable	
Special precautions for user	Special provisions	A3
	Cargo Only Packing Instructions	364
	Cargo Only Maximum Qty / Pack	60 L
	Passenger and Cargo Packing Instructions	353
	Passenger and Cargo Maximum Qty / Pack	5 L
	Passenger and Cargo Limited Quantity Packing Instructions	Y341
	Passenger and Cargo Limited Maximum Qty / Pack	1 L

Sea transport (IMDG-Code / GGVSee)

UN number	1133	
UN proper shipping name	ADHESIVES containing flammable liquid	
Transport hazard class(es)	IMDG Class	3
	IMDG Subrisk	Not Applicable
Packing group	II	
Environmental hazard	Not Applicable	
Special precautions for user	EMS Number	F-E , S-D
	Special provisions	Not Applicable
	Limited Quantities	5 L

Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
toluene	Not Available
naphtha petroleum, light solvent-refined	Not Available
chloroprene homopolymer	Not Available
acetone	Not Available
xylene	Not Available
styrene	Not Available
magnesium oxide	Not Available
zinc oxide	Not Available

Transport in bulk in accordance with the ICG Code

Product name	Ship Type
toluene	Not Available
naphtha petroleum, light solvent-refined	Not Available
chloroprene homopolymer	Not Available
acetone	Not Available
xylene	Not Available
styrene	Not Available
magnesium oxide	Not Available
zinc oxide	Not Available

SECTION 15 Regulatory information**Safety, health and environmental regulations / legislation specific for the substance or mixture**

This substance is to be managed using the conditions specified in an applicable Group Standard

HSR Number	Group Standard
HSR002502	Additives Process Chemicals and Raw Materials Flammable Carcinogenic Group Standard 2020

Please refer to Section 8 of the SDS for any applicable tolerable exposure limit or Section 12 for environmental exposure limit.

toluene is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

New Zealand Approved Hazardous Substances with controls

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data

New Zealand Inventory of Chemicals (NZIoC)

New Zealand Workplace Exposure Standards (WES)

naphtha petroleum, light solvent-refined is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 1: Carcinogenic to humans

New Zealand Approved Hazardous Substances with controls

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals

New Zealand Inventory of Chemicals (NZIoC)

New Zealand Workplace Exposure Standards (WES)

chloroprene homopolymer is found on the following regulatory lists

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

New Zealand Inventory of Chemicals (NZIoC)

New Zealand Workplace Exposure Standards (WES)

acetone is found on the following regulatory lists

New Zealand Approved Hazardous Substances with controls

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data

New Zealand Inventory of Chemicals (NZIoC)

New Zealand Workplace Exposure Standards (WES)

xylene is found on the following regulatory lists

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

New Zealand Approved Hazardous Substances with controls

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data

New Zealand Inventory of Chemicals (NZIoC)

New Zealand Workplace Exposure Standards (WES)

styrene is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs
International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2A: Probably carcinogenic to humans
New Zealand Approved Hazardous Substances with controls

New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals
New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data
New Zealand Inventory of Chemicals (NZIoC)
New Zealand Workplace Exposure Standards (WES)

magnesium oxide is found on the following regulatory lists

New Zealand Approved Hazardous Substances with controls
New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals
New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data

New Zealand Inventory of Chemicals (NZIoC)
New Zealand Workplace Exposure Standards (WES)

zinc oxide is found on the following regulatory lists

New Zealand Approved Hazardous Substances with controls
New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals
New Zealand Hazardous Substances and New Organisms (HSNO) Act - Classification of Chemicals - Classification Data

New Zealand Inventory of Chemicals (NZIoC)
New Zealand Workplace Exposure Standards (WES)

Hazardous Substance Location

Subject to the Health and Safety at Work (Hazardous Substances) Regulations 2017.

Hazard Class	Quantity (Closed Containers)	Quantity (Open Containers)
3.1B	100 L in containers more than 5 L	50 L
3.1B	250 L in containers up to and including 5 L	50 L

Certified Handler

Subject to Part 4 of the Health and Safety at Work (Hazardous Substances) Regulations 2017.

Class of substance	Quantities
Not Applicable	Not Applicable

Refer Group Standards for further information

Maximum quantities of certain hazardous substances permitted on passenger service vehicles

Subject to Regulation 13.14 of the Health and Safety at Work (Hazardous Substances) Regulations 2017.

Hazard Class	Gas (aggregate water capacity in mL)	Liquid (L)	Solid (kg)	Maximum quantity per package for each classification
6.5A or 6.5B	120	1	3	
3.1B				1 L

Tracking Requirements

Not Applicable

National Inventory Status

National Inventory	Status
Australia - AIIC / Australia Non-Industrial Use	Yes
Canada - DSL	Yes
Canada - NDSL	No (toluene; naphtha petroleum, light solvent-refined; chloroprene homopolymer; acetone; xylene; styrene; magnesium oxide)
China - IECSC	Yes
Europe - EINEC / ELINCS / NLP	No (chloroprene homopolymer)
Japan - ENCS	No (naphtha petroleum, light solvent-refined)
Korea - KECI	Yes
New Zealand - NZIoC	Yes
Philippines - PICCS	Yes
USA - TSCA	Yes
Taiwan - TCSI	Yes
Mexico - INSQ	No (naphtha petroleum, light solvent-refined)
Vietnam - NCI	Yes
Russia - FBEPH	Yes
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.

SECTION 16 Other information

Revision Date	17/12/2021
Initial Date	17/12/2021

SDS Version Summary

Version	Date of Update	Sections Updated
2.1	17/12/2021	Appearance, Classification

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average
 PC—STEL: Permissible Concentration-Short Term Exposure Limit
 IARC: International Agency for Research on Cancer
 ACGIH: American Conference of Governmental Industrial Hygienists
 STEL: Short Term Exposure Limit
 TEEL: Temporary Emergency Exposure Limit.
 IDLH: Immediately Dangerous to Life or Health Concentrations
 ES: Exposure Standard
 OSF: Odour Safety Factor
 NOAEL :No Observed Adverse Effect Level
 LOAEL: Lowest Observed Adverse Effect Level
 TLV: Threshold Limit Value
 LOD: Limit Of Detection
 OTV: Odour Threshold Value
 BCF: BioConcentration Factors
 BEI: Biological Exposure Index
 AIIIC: Australian Inventory of Industrial Chemicals
 DSL: Domestic Substances List
 NDSL: Non-Domestic Substances List
 IECSC: Inventory of Existing Chemical Substance in China
 EINECS: European INventory of Existing Commercial chemical Substances
 ELINCS: European List of Notified Chemical Substances
 NLP: No-Longer Polymers
 ENCS: Existing and New Chemical Substances Inventory
 KECl: Korea Existing Chemicals Inventory
 NZIoC: New Zealand Inventory of Chemicals
 PICCS: Philippine Inventory of Chemicals and Chemical Substances
 TSCA: Toxic Substances Control Act
 TCST: Taiwan Chemical Substance Inventory
 INSQ: Inventario Nacional de Sustancias Químicas
 NCI: National Chemical Inventory
 FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.